AU767962B2 - Mammaglobin, a secreted mammary-specific breast cancer protein - Google Patents
Mammaglobin, a secreted mammary-specific breast cancer protein Download PDFInfo
- Publication number
- AU767962B2 AU767962B2 AU62758/99A AU6275899A AU767962B2 AU 767962 B2 AU767962 B2 AU 767962B2 AU 62758/99 A AU62758/99 A AU 62758/99A AU 6275899 A AU6275899 A AU 6275899A AU 767962 B2 AU767962 B2 AU 767962B2
- Authority
- AU
- Australia
- Prior art keywords
- mammaglobin
- seq
- cdna
- breast
- mrna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 208000026310 Breast neoplasm Diseases 0.000 title claims description 87
- 206010006187 Breast cancer Diseases 0.000 title claims description 75
- 108090000623 proteins and genes Proteins 0.000 title description 96
- 102000004169 proteins and genes Human genes 0.000 title description 74
- 210000004027 cell Anatomy 0.000 claims description 90
- 206010028980 Neoplasm Diseases 0.000 claims description 84
- 238000000034 method Methods 0.000 claims description 77
- 239000002299 complementary DNA Substances 0.000 claims description 76
- 108020004999 messenger RNA Proteins 0.000 claims description 56
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 54
- 210000000481 breast Anatomy 0.000 claims description 41
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 37
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 27
- 239000012634 fragment Substances 0.000 claims description 23
- 229920001184 polypeptide Polymers 0.000 claims description 23
- 238000003752 polymerase chain reaction Methods 0.000 claims description 22
- 238000009396 hybridization Methods 0.000 claims description 19
- 210000001165 lymph node Anatomy 0.000 claims description 19
- 108091034117 Oligonucleotide Proteins 0.000 claims description 13
- 230000009826 neoplastic cell growth Effects 0.000 claims description 13
- 108091033319 polynucleotide Proteins 0.000 claims description 13
- 102000040430 polynucleotide Human genes 0.000 claims description 13
- 239000002157 polynucleotide Substances 0.000 claims description 13
- 230000000295 complement effect Effects 0.000 claims description 12
- 230000002093 peripheral effect Effects 0.000 claims description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 6
- 210000000265 leukocyte Anatomy 0.000 claims description 4
- 238000010839 reverse transcription Methods 0.000 claims description 4
- 238000007834 ligase chain reaction Methods 0.000 claims description 3
- 235000018102 proteins Nutrition 0.000 description 70
- 210000001519 tissue Anatomy 0.000 description 53
- 239000000523 sample Substances 0.000 description 46
- 230000014509 gene expression Effects 0.000 description 44
- 241000282414 Homo sapiens Species 0.000 description 41
- 108091007433 antigens Proteins 0.000 description 41
- 102000036639 antigens Human genes 0.000 description 41
- 239000000427 antigen Substances 0.000 description 40
- 210000003719 b-lymphocyte Anatomy 0.000 description 37
- 210000004881 tumor cell Anatomy 0.000 description 33
- 235000001014 amino acid Nutrition 0.000 description 32
- 229940024606 amino acid Drugs 0.000 description 29
- 150000001413 amino acids Chemical class 0.000 description 29
- 238000006243 chemical reaction Methods 0.000 description 25
- 238000001514 detection method Methods 0.000 description 24
- 201000011510 cancer Diseases 0.000 description 22
- 238000010186 staining Methods 0.000 description 21
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 19
- 241000283973 Oryctolagus cuniculus Species 0.000 description 19
- 229960005486 vaccine Drugs 0.000 description 19
- 239000013615 primer Substances 0.000 description 17
- 239000000047 product Substances 0.000 description 16
- 239000000203 mixture Substances 0.000 description 15
- 239000002243 precursor Substances 0.000 description 14
- 230000003321 amplification Effects 0.000 description 12
- 239000000872 buffer Substances 0.000 description 12
- 238000003199 nucleic acid amplification method Methods 0.000 description 12
- 108010018777 Prostatein Proteins 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 210000002307 prostate Anatomy 0.000 description 11
- 238000001262 western blot Methods 0.000 description 11
- 239000013592 cell lysate Substances 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 9
- 108010066302 Keratin-19 Proteins 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- 230000002441 reversible effect Effects 0.000 description 9
- 238000013519 translation Methods 0.000 description 9
- 230000014616 translation Effects 0.000 description 9
- 241000283707 Capra Species 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 8
- 230000001605 fetal effect Effects 0.000 description 8
- 210000005075 mammary gland Anatomy 0.000 description 8
- 230000002018 overexpression Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 7
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 7
- 101000583175 Homo sapiens Prolactin-inducible protein Proteins 0.000 description 7
- 108010031029 Mammaglobin B Proteins 0.000 description 7
- 102000005722 Mammaglobin B Human genes 0.000 description 7
- 102100030350 Prolactin-inducible protein Human genes 0.000 description 7
- 108091058545 Secretory proteins Proteins 0.000 description 7
- 102000040739 Secretory proteins Human genes 0.000 description 7
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 7
- 108090000203 Uteroglobin Proteins 0.000 description 7
- 230000000890 antigenic effect Effects 0.000 description 7
- 239000003636 conditioned culture medium Substances 0.000 description 7
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 7
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000000636 Northern blotting Methods 0.000 description 6
- 108010006785 Taq Polymerase Proteins 0.000 description 6
- 102000003848 Uteroglobin Human genes 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 206010061289 metastatic neoplasm Diseases 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 210000004291 uterus Anatomy 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000004988 N-glycosylation Effects 0.000 description 5
- 210000000612 antigen-presenting cell Anatomy 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 201000008275 breast carcinoma Diseases 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 5
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 5
- 238000003018 immunoassay Methods 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229960004452 methionine Drugs 0.000 description 5
- 235000006109 methionine Nutrition 0.000 description 5
- 238000004393 prognosis Methods 0.000 description 5
- 210000001995 reticulocyte Anatomy 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 239000000439 tumor marker Substances 0.000 description 5
- 206010055113 Breast cancer metastatic Diseases 0.000 description 4
- 101800001415 Bri23 peptide Proteins 0.000 description 4
- 102400000107 C-terminal peptide Human genes 0.000 description 4
- 101800000655 C-terminal peptide Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 4
- 102100034343 Integrase Human genes 0.000 description 4
- 108091054437 MHC class I family Proteins 0.000 description 4
- 102000043131 MHC class II family Human genes 0.000 description 4
- 108091054438 MHC class II family Proteins 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 210000000069 breast epithelial cell Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000012303 cytoplasmic staining Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 4
- 230000008482 dysregulation Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000009607 mammography Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 230000001613 neoplastic effect Effects 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 210000003079 salivary gland Anatomy 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 208000006402 Ductal Carcinoma Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- HSJIGJRZYUADSS-IHRRRGAJSA-N Met-Lys-Leu Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O HSJIGJRZYUADSS-IHRRRGAJSA-N 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 238000010222 PCR analysis Methods 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 108010038633 aspartylglutamate Proteins 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 102000023732 binding proteins Human genes 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 210000000172 cytosol Anatomy 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 238000002991 immunohistochemical analysis Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 210000002826 placenta Anatomy 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- -1 radionuclides Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- HQJKCXHQNUCKMY-GHCJXIJMSA-N Ala-Ile-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](C)N HQJKCXHQNUCKMY-GHCJXIJMSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- YNQIDCRRTWGHJD-ZLUOBGJFSA-N Asp-Asn-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC(O)=O YNQIDCRRTWGHJD-ZLUOBGJFSA-N 0.000 description 2
- MGSVBZIBCCKGCY-ZLUOBGJFSA-N Asp-Ser-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MGSVBZIBCCKGCY-ZLUOBGJFSA-N 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 102000003910 Cyclin D Human genes 0.000 description 2
- 108090000259 Cyclin D Proteins 0.000 description 2
- RESAHOSBQHMOKH-KKUMJFAQSA-N Cys-Phe-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CS)N RESAHOSBQHMOKH-KKUMJFAQSA-N 0.000 description 2
- BVTJGGGYKAMDBN-UHFFFAOYSA-N Dioxetane Chemical class C1COO1 BVTJGGGYKAMDBN-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- IVGJYOOGJLFKQE-AVGNSLFASA-N Glu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N IVGJYOOGJLFKQE-AVGNSLFASA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 239000012741 Laemmli sample buffer Substances 0.000 description 2
- RRSLQOLASISYTB-CIUDSAMLSA-N Leu-Cys-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(O)=O RRSLQOLASISYTB-CIUDSAMLSA-N 0.000 description 2
- NRFGTHFONZYFNY-MGHWNKPDSA-N Leu-Ile-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NRFGTHFONZYFNY-MGHWNKPDSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 102000015728 Mucins Human genes 0.000 description 2
- 108010063954 Mucins Proteins 0.000 description 2
- 101000777235 Mus musculus Uteroglobin Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 241000276498 Pollachius virens Species 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- SVWQEIRZHHNBIO-WHFBIAKZSA-N Ser-Gly-Cys Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CS)C(O)=O SVWQEIRZHHNBIO-WHFBIAKZSA-N 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- YBXMGKCLOPDEKA-NUMRIWBASA-N Thr-Asp-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O YBXMGKCLOPDEKA-NUMRIWBASA-N 0.000 description 2
- PAXANSWUSVPFNK-IUKAMOBKSA-N Thr-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N PAXANSWUSVPFNK-IUKAMOBKSA-N 0.000 description 2
- YOOAQCZYZHGUAZ-KATARQTJSA-N Thr-Leu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YOOAQCZYZHGUAZ-KATARQTJSA-N 0.000 description 2
- AAZOYLQUEQRUMZ-GSSVUCPTSA-N Thr-Thr-Asn Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(N)=O AAZOYLQUEQRUMZ-GSSVUCPTSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- QTPQHINADBYBNA-DCAQKATOSA-N Val-Ser-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN QTPQHINADBYBNA-DCAQKATOSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000003150 biochemical marker Substances 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000233 bronchiolar non-ciliated Anatomy 0.000 description 2
- 229940023860 canarypox virus HIV vaccine Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 108091092328 cellular RNA Proteins 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002357 endometrial effect Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000004077 genetic alteration Effects 0.000 description 2
- 231100000118 genetic alteration Toxicity 0.000 description 2
- 108010073628 glutamyl-valyl-phenylalanine Proteins 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000000174 oncolytic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 229940051022 radioimmunoconjugate Drugs 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000003270 steroid hormone Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- JNTMAZFVYNDPLB-PEDHHIEDSA-N (2S,3S)-2-[[[(2S)-1-[(2S,3S)-2-amino-3-methyl-1-oxopentyl]-2-pyrrolidinyl]-oxomethyl]amino]-3-methylpentanoic acid Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JNTMAZFVYNDPLB-PEDHHIEDSA-N 0.000 description 1
- BEJKOYIMCGMNRB-GRHHLOCNSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-amino-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 BEJKOYIMCGMNRB-GRHHLOCNSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- KJDSORYAHBAGPP-UHFFFAOYSA-N 4-(3,4-diaminophenyl)benzene-1,2-diamine;hydron;tetrachloride Chemical compound Cl.Cl.Cl.Cl.C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 KJDSORYAHBAGPP-UHFFFAOYSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
- VBDMWOKJZDCFJM-FXQIFTODSA-N Ala-Ala-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)N VBDMWOKJZDCFJM-FXQIFTODSA-N 0.000 description 1
- WGDNWOMKBUXFHR-BQBZGAKWSA-N Ala-Gly-Arg Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N WGDNWOMKBUXFHR-BQBZGAKWSA-N 0.000 description 1
- NBTGEURICRTMGL-WHFBIAKZSA-N Ala-Gly-Ser Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O NBTGEURICRTMGL-WHFBIAKZSA-N 0.000 description 1
- QCTFKEJEIMPOLW-JURCDPSOSA-N Ala-Ile-Phe Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QCTFKEJEIMPOLW-JURCDPSOSA-N 0.000 description 1
- SOBIAADAMRHGKH-CIUDSAMLSA-N Ala-Leu-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O SOBIAADAMRHGKH-CIUDSAMLSA-N 0.000 description 1
- RTZCUEHYUQZIDE-WHFBIAKZSA-N Ala-Ser-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RTZCUEHYUQZIDE-WHFBIAKZSA-N 0.000 description 1
- XCIGOVDXZULBBV-DCAQKATOSA-N Ala-Val-Lys Chemical compound CC(C)[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](CCCCN)C(O)=O XCIGOVDXZULBBV-DCAQKATOSA-N 0.000 description 1
- FMYQECOAIFGQGU-CYDGBPFRSA-N Arg-Val-Ile Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FMYQECOAIFGQGU-CYDGBPFRSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- MYRLSKYSMXNLLA-LAEOZQHASA-N Asn-Val-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O MYRLSKYSMXNLLA-LAEOZQHASA-N 0.000 description 1
- ZAESWDKAMDVHLL-RCOVLWMOSA-N Asn-Val-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O ZAESWDKAMDVHLL-RCOVLWMOSA-N 0.000 description 1
- JNCRAQVYJZGIOW-QSFUFRPTSA-N Asn-Val-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JNCRAQVYJZGIOW-QSFUFRPTSA-N 0.000 description 1
- RWHHSFSWKFBTCF-KKUMJFAQSA-N Asp-His-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC(=O)O)N RWHHSFSWKFBTCF-KKUMJFAQSA-N 0.000 description 1
- RPUYTJJZXQBWDT-SRVKXCTJSA-N Asp-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC(=O)O)N RPUYTJJZXQBWDT-SRVKXCTJSA-N 0.000 description 1
- WOKXEQLPBLLWHC-IHRRRGAJSA-N Asp-Tyr-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 WOKXEQLPBLLWHC-IHRRRGAJSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 101150071258 C3 gene Proteins 0.000 description 1
- 241000178270 Canarypox virus Species 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- AYKQJQVWUYEZNU-IMJSIDKUSA-N Cys-Asn Chemical compound SC[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O AYKQJQVWUYEZNU-IMJSIDKUSA-N 0.000 description 1
- OABOXRPGTFRBFZ-IMJSIDKUSA-N Cys-Cys Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(O)=O OABOXRPGTFRBFZ-IMJSIDKUSA-N 0.000 description 1
- GHUVBPIYQYXXEF-SRVKXCTJSA-N Cys-Cys-Tyr Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 GHUVBPIYQYXXEF-SRVKXCTJSA-N 0.000 description 1
- XZFYRXDAULDNFX-UWVGGRQHSA-N Cys-Phe Chemical compound SC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UWVGGRQHSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 239000012983 Dulbecco’s minimal essential medium Substances 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 240000002989 Euphorbia neriifolia Species 0.000 description 1
- 108091060211 Expressed sequence tag Proteins 0.000 description 1
- 101150096839 Fcmr gene Proteins 0.000 description 1
- PCBBLFVHTYNQGG-LAEOZQHASA-N Glu-Asn-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)O)N PCBBLFVHTYNQGG-LAEOZQHASA-N 0.000 description 1
- FVGOGEGGQLNZGH-DZKIICNBSA-N Glu-Val-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FVGOGEGGQLNZGH-DZKIICNBSA-N 0.000 description 1
- UEGIPZAXNBYCCP-NKWVEPMBSA-N Gly-Cys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CS)NC(=O)CN)C(=O)O UEGIPZAXNBYCCP-NKWVEPMBSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- WOAMZMXCLBBQKW-KKUMJFAQSA-N His-Cys-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC2=CN=CN2)N)O WOAMZMXCLBBQKW-KKUMJFAQSA-N 0.000 description 1
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101500025239 Homo sapiens Eosinophil granule major basic protein Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000777301 Homo sapiens Uteroglobin Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- UKTUOMWSJPXODT-GUDRVLHUSA-N Ile-Asn-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N UKTUOMWSJPXODT-GUDRVLHUSA-N 0.000 description 1
- VGSPNSSCMOHRRR-BJDJZHNGSA-N Ile-Ser-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N VGSPNSSCMOHRRR-BJDJZHNGSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KFKWRHQBZQICHA-STQMWFEESA-N L-leucyl-L-phenylalanine Natural products CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KFKWRHQBZQICHA-STQMWFEESA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- QNBVTHNJGCOVFA-AVGNSLFASA-N Leu-Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O QNBVTHNJGCOVFA-AVGNSLFASA-N 0.000 description 1
- PPQRKXHCLYCBSP-IHRRRGAJSA-N Leu-Leu-Met Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)O)N PPQRKXHCLYCBSP-IHRRRGAJSA-N 0.000 description 1
- KPYAOIVPJKPIOU-KKUMJFAQSA-N Leu-Lys-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O KPYAOIVPJKPIOU-KKUMJFAQSA-N 0.000 description 1
- DDVHDMSBLRAKNV-IHRRRGAJSA-N Leu-Met-Leu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O DDVHDMSBLRAKNV-IHRRRGAJSA-N 0.000 description 1
- NJMXCOOEFLMZSR-AVGNSLFASA-N Leu-Met-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(O)=O NJMXCOOEFLMZSR-AVGNSLFASA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 206010073099 Lobular breast carcinoma in situ Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- DCRWPTBMWMGADO-AVGNSLFASA-N Lys-Glu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O DCRWPTBMWMGADO-AVGNSLFASA-N 0.000 description 1
- SLQJJFAVWSZLBL-BJDJZHNGSA-N Lys-Ile-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCCCN SLQJJFAVWSZLBL-BJDJZHNGSA-N 0.000 description 1
- LJADEBULDNKJNK-IHRRRGAJSA-N Lys-Leu-Val Chemical compound CC(C)C[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O LJADEBULDNKJNK-IHRRRGAJSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- ZYTPOUNUXRBYGW-YUMQZZPRSA-N Met-Met Chemical compound CSCC[C@H]([NH3+])C(=O)N[C@H](C([O-])=O)CCSC ZYTPOUNUXRBYGW-YUMQZZPRSA-N 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 206010027454 Metastases to breast Diseases 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- XZFYRXDAULDNFX-UHFFFAOYSA-N N-L-cysteinyl-L-phenylalanine Natural products SCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 101100386053 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cys-3 gene Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- GYEPCBNTTRORKW-PCBIJLKTSA-N Phe-Ile-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O GYEPCBNTTRORKW-PCBIJLKTSA-N 0.000 description 1
- YTILBRIUASDGBL-BZSNNMDCSA-N Phe-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 YTILBRIUASDGBL-BZSNNMDCSA-N 0.000 description 1
- FADYJNXDPBKVCA-STQMWFEESA-N Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 FADYJNXDPBKVCA-STQMWFEESA-N 0.000 description 1
- 231100000742 Plant toxin Toxicity 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- XYSXOCIWCPFOCG-IHRRRGAJSA-N Pro-Leu-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O XYSXOCIWCPFOCG-IHRRRGAJSA-N 0.000 description 1
- AFWBWPCXSWUCLB-WDSKDSINSA-N Pro-Ser Chemical compound OC[C@@H](C([O-])=O)NC(=O)[C@@H]1CCC[NH2+]1 AFWBWPCXSWUCLB-WDSKDSINSA-N 0.000 description 1
- FIDNSJUXESUDOV-JYJNAYRXSA-N Pro-Tyr-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O FIDNSJUXESUDOV-JYJNAYRXSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 101710086015 RNA ligase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 101710141795 Ribonuclease inhibitor Proteins 0.000 description 1
- 229940122208 Ribonuclease inhibitor Drugs 0.000 description 1
- 102100037968 Ribonuclease inhibitor Human genes 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 101150064359 SLC6A1 gene Proteins 0.000 description 1
- JPIDMRXXNMIVKY-VZFHVOOUSA-N Ser-Ala-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JPIDMRXXNMIVKY-VZFHVOOUSA-N 0.000 description 1
- FFOKMZOAVHEWET-IMJSIDKUSA-N Ser-Cys Chemical compound OC[C@H](N)C(=O)N[C@@H](CS)C(O)=O FFOKMZOAVHEWET-IMJSIDKUSA-N 0.000 description 1
- HBTCFCHYALPXME-HTFCKZLJSA-N Ser-Ile-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HBTCFCHYALPXME-HTFCKZLJSA-N 0.000 description 1
- RIAKPZVSNBBNRE-BJDJZHNGSA-N Ser-Ile-Leu Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O RIAKPZVSNBBNRE-BJDJZHNGSA-N 0.000 description 1
- IAORETPTUDBBGV-CIUDSAMLSA-N Ser-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N IAORETPTUDBBGV-CIUDSAMLSA-N 0.000 description 1
- LRZLZIUXQBIWTB-KATARQTJSA-N Ser-Lys-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LRZLZIUXQBIWTB-KATARQTJSA-N 0.000 description 1
- ZKBKUWQVDWWSRI-BZSNNMDCSA-N Ser-Phe-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZKBKUWQVDWWSRI-BZSNNMDCSA-N 0.000 description 1
- HHJFMHQYEAAOBM-ZLUOBGJFSA-N Ser-Ser-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O HHJFMHQYEAAOBM-ZLUOBGJFSA-N 0.000 description 1
- BDMWLJLPPUCLNV-XGEHTFHBSA-N Ser-Thr-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O BDMWLJLPPUCLNV-XGEHTFHBSA-N 0.000 description 1
- SIEBDTCABMZCLF-XGEHTFHBSA-N Ser-Val-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SIEBDTCABMZCLF-XGEHTFHBSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000017274 T cell anergy Effects 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 101000865057 Thermococcus litoralis DNA polymerase Proteins 0.000 description 1
- GNHRVXYZKWSJTF-HJGDQZAQSA-N Thr-Asp-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N)O GNHRVXYZKWSJTF-HJGDQZAQSA-N 0.000 description 1
- HJOSVGCWOTYJFG-WDCWCFNPSA-N Thr-Glu-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N)O HJOSVGCWOTYJFG-WDCWCFNPSA-N 0.000 description 1
- LKEKWDJCJSPXNI-IRIUXVKKSA-N Thr-Glu-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 LKEKWDJCJSPXNI-IRIUXVKKSA-N 0.000 description 1
- XIULAFZYEKSGAJ-IXOXFDKPSA-N Thr-Leu-His Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 XIULAFZYEKSGAJ-IXOXFDKPSA-N 0.000 description 1
- NDXSOKGYKCGYKT-VEVYYDQMSA-N Thr-Pro-Asp Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O NDXSOKGYKCGYKT-VEVYYDQMSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- VFJIWSJKZJTQII-SRVKXCTJSA-N Tyr-Asp-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O VFJIWSJKZJTQII-SRVKXCTJSA-N 0.000 description 1
- JLKVWTICWVWGSK-JYJNAYRXSA-N Tyr-Lys-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 JLKVWTICWVWGSK-JYJNAYRXSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- OVLIFGQSBSNGHY-KKHAAJSZSA-N Val-Asp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)N)O OVLIFGQSBSNGHY-KKHAAJSZSA-N 0.000 description 1
- KDKLLPMFFGYQJD-CYDGBPFRSA-N Val-Ile-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](C(C)C)N KDKLLPMFFGYQJD-CYDGBPFRSA-N 0.000 description 1
- HJSLDXZAZGFPDK-ULQDDVLXSA-N Val-Phe-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](C(C)C)N HJSLDXZAZGFPDK-ULQDDVLXSA-N 0.000 description 1
- ZEBRMWPTJNHXAJ-JYJNAYRXSA-N Val-Phe-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(=O)O)N ZEBRMWPTJNHXAJ-JYJNAYRXSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 108010081404 acein-2 Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 1
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000002210 apocrine cell Anatomy 0.000 description 1
- 210000000040 apocrine gland Anatomy 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 108010077245 asparaginyl-proline Proteins 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- MPZXRQDDGXXWEY-UHFFFAOYSA-N benzene-1,2-diamine;tetrahydrochloride Chemical compound Cl.Cl.Cl.Cl.NC1=CC=CC=C1N MPZXRQDDGXXWEY-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 201000005389 breast carcinoma in situ Diseases 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000001159 caudate nucleus Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- HRBKVYFZANMGRE-UHFFFAOYSA-N chlorpyrifos-methyl Chemical compound COP(=S)(OC)OC1=NC(Cl)=C(Cl)C=C1Cl HRBKVYFZANMGRE-UHFFFAOYSA-N 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 210000002726 cyst fluid Anatomy 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 108010004073 cysteinylcysteine Proteins 0.000 description 1
- 108010060199 cysteinylproline Proteins 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 108010054812 diprotin A Proteins 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 201000007273 ductal carcinoma in situ Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 230000009786 epithelial differentiation Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002458 fetal heart Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 230000004545 gene duplication Effects 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000017555 immunoglobulin mediated immune response Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 108010044056 leucyl-phenylalanine Proteins 0.000 description 1
- 108010091871 leucylmethionine Proteins 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 201000011059 lobular neoplasia Diseases 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 210000001767 medulla oblongata Anatomy 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 150000002742 methionines Chemical class 0.000 description 1
- 108010085203 methionylmethionine Proteins 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000000869 occipital lobe Anatomy 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 239000003123 plant toxin Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108010031719 prolyl-serine Proteins 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 210000002637 putamen Anatomy 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000002976 reverse transcriptase assay Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000012409 standard PCR amplification Methods 0.000 description 1
- 108020003178 steroid binding proteins Proteins 0.000 description 1
- 102000005963 steroid binding proteins Human genes 0.000 description 1
- 230000000365 steroidogenetic effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 108010051110 tyrosyl-lysine Proteins 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4721—Lipocortins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Description
WO 00/18783 PCT/US99/22616 MAMMAGLOBIN, A SECRETED MAMMARY-SPECIFIC BREAST CANCER
PROTEIN
Related Applications This application is a continuation-in-part of U.S. Application No. 08/933,149, filed September 18, 1997, which is a continuation-in-part of PCT/US96/08235, filed May 31, 1996 and a continuation-in-part of U.S. Application No. 08/455,896, filed May 31, 1995, now U.S. Patent No. 5,668,267.
Reference to Government Grants This invention was made with government support under Public Health Service Grants CA76227, CA76223-01 and CA68485. The government has certain rights in this invention.
Background of the Invention Field of the Invention This invention relates generally to the field of breast cancer pathogenesis and, more particularly, to a cDNA sequence and encoded mammary-specific protein for use in detecting and treating breast cancer.
Description of the Related Art i WO 00/18783 PCT/US99/22616 2 Breast cancer is one of the most common and potentially lethal of cancers.
Although early diagnosis and treatment can reduce morbidity and mortality related to the disease, the positive predictive value of mammography has been estimated to be only about 25% (Hall et al., NEngl JMed327:319-328, 1992). It would, therefore, be desirable to have a means for detecting the cancer earlier than the cancer can be detected using mammography and a genetic or biochemical marker might be able to provide such means to complement and increase the predictive value of mammography. (Hayes, Hematol Oncol Clin NAm 8:485, 1994).
The development of breast cancer is accompanied by a number of genetic changes (For review see Porter-Jordan, Hematol Oncol Clin NAm 8:73, 1994). Such changes include gross chromosomal alterations and loss of genetic markers (Devilee et al, Biochim Biophys Acta 1198:113, 1994; Callahan et al, J Cell Biochemn Suppl 17:167, 1993). The progression of breast neoplasia has also been shown to result in qualitative and quantitative changes in expression of previously identified genes that encode growth factors and their receptors (Zajchowski et al., Cancer Res 48:7041, 1988), structural proteins (Trask et al., Proc Natl Acad Sci 87:2319, 1990), second messenger proteins (Ohuchi et al., Cancer Res 26:251 1, 1986), and transcription factors (Harris, Adv Cancer Res 59:69:1992). These changes in gene expression could potentially form the basis for developing a breast cancer marker, although the precise role of these gene changes in the pathogenesis of breast carcinoma in patient biopsy samples is not well understood.
In addition to providing a genetic or biochemical marker for breast cancer for early detection of the disease, it would also be desirable to have a tumor marker that might provide an estimation of prognosis, a means for selection and evaluation of therapy and a means for the targeting of therapy. Although a number of tissue markers have been identified, none are sufficiently sensitive or tumor specific to be ideally suited for diagnosis or for screening the general population. Thus, there remains a continuing need for a breast cancer marker such as a gene along with its expressed protein that can be used to specifically and selectively identify the appearance and pathogenic development of breast cancer in a patient, and that can be used in tumor-specific immunotherapy.
WO 00/18783 PCTn[S99/22616 3 Using a modified differential display polymerase chain reaction technique to isolate differentially expressed sequence tags from mammary carcinoma, several sequence fragments were isolated that were uniquely expressed in neoplastic mammary epithelial tissue as compared to normal tissue controls (Watson and Fleming, Cancer Res 54:4598-4602, 1994). The discovery of one of these sequence tags identified as DEST002 has led to the discovery and isolation of the novel full length cDNA and encoded protein now referenced as mammaglobin. The cDNA and protein are both new.
Summary of the Invention Briefly, therefore, the present invention is directed to the identification of novel genes whose expression is increased in breast cancer and to the isolating of cDNA's from the mRNA's of these genes. Accordingly, applicants have succeeded in discovering a novel cDNA and the encoded mammary-specific secretory protein, mammaglobin. The cDNA is in purified and isolated form and comprises a nucleotide sequence identified as SEQ ID NO: 15 and the encoded protein, mammaglobin, is in purified and isolated form and has an amino acid sequence identified as SEQ ID NO:2.
In a small-scale study described in U.S. Patent No. 5,668,267, mammaglobin mRNA was overexpressed in 27% of stage I primary breast cancer tumors. The present application describes a larger survey of primary breast tumors of multiple grades and histological types in which mammaglobin protein was detected in about of the tumors examined. These data suggest that dysregulation of the mammaglobin gene occurs early and frequently in breast cancer. The discovery of mammaglobin and its cDNA, therefore, provide the basis for the development of novel methods and compositions for the detection and treatment of breast neoplastic disease in humans and other mammals.
Thus, the present invention is directed to novel methods for detecting the presence of breast neoplasia cells in a sample. In one embodiment, a polynucleotide probe is used to detect the presence of mammaglobin mRNA in the sample. The method comprises the steps of: contacting mRNA in the sample with a polynucleotide probe which specifically hybridizes to a mammaglobin mRNA WO 00/18783 PCT/US99/22616 4 comprising SEQ ID NO: 15 or an allelic variant thereof, and detecting a hybridization complex between the probe and the sample mRNA.
Another aspect of the present invention provides a kit for detecting the presence of breast neoplasia cells in a sample by hybridization. The kit comprises a polynucleotide probe which specifically hybridizes to a mammaglobin mRNA comprising SEQ ID NO: 15 or an allelic variant thereof packaged in a container.
In another embodiment of the present invention, mammaglobin expression in a sample is determined by detecting the presence of cDNA that is reverse transcribed from mammaglobin mRNA in the sample. The method comprises the steps of: (a) producing a cDNA encoding mammaglobin from mRNA using the reverse transcription method in a sample obtained from a patient, providing two primers for the polymerase chain reaction method which comprise oligomers that flank or lie within the cDNA encoding mammaglobin, and amplifying the cDNA encoding mammaglobin by the polymerase chain reaction method. Preferably, the two primers have nucleotide sequences encoding SEQ ID NO:4 and SEQ ID NO: 16.
Another embodiment to the present invention provides a kit for detecting the presence of breast neoplasia cells in a sample by the polymerase chain reaction. The kit comprises two primers for the polymerase chain reaction method which comprise oligomers that flank or lie within a cDNA encoding mammaglobin packaged in a container. Preferably, the two primers have nucleotide sequences comprising SEQ ID NO:4 and SEQ ID NO:16.
In another embodiment of the present invention, the presence of mammaglobin protein expressed by a tumor cell is detected in a sample using specific antibodies to the mammaglobin protein. The specific antibodies can be polyclonal or monoclonal antibodies.
The invention is also directed to novel compositions and methods for treating breast neoplastic disease using mammaglobin antigens capable of inducing an antibody-mediated and/or a cell-mediated, through activated T cells, immune response against a mammaglobin-expressing tumor.
One embodiment of a composition according to the invention comprises a mammaglobin B cell antigen capable of activating mammaglobin-specific B cells.
WO 00/18783 PCT/US99/22616 The B cell antigen comprises a mammaglobin-specific B cell epitope and a TH epitope, or determinant, recognized by T helper cells.
In another embodiment, the mammaglobin antigen is a mammaglobin Tc cell antigen recognized by mammaglobin-specific cytotoxic T lymphocytes which comprises a Tc cell epitope and a binding site, or agretope, for a MHC class I molecule.
Yet another embodiment of a composition according to the invention comprises B cell and Tc cell antigens.
Methods for treating a patient with a mammaglobin-expressing tumor include adoptive immunotherapy, which comprises ex vivo stimulation with a mammaglobin antigen of mammaglobin-specific lymphocytes isolated from the patient and subsequent administration of the activated lymphocytes to the patient, and in vivo stimulation of an anti-mammaglobin immune response, which comprises administering to the patient a vaccine comprising a mammaglobin antigen.
Among the several advantages found to be achieved by the present invention, therefore, may be noted the provision of a nucleotide sequence and encoded amino acid sequence that can serve as markers for breast cancer cells; the provision of methods for early detection of the presence of breast neoplasia cells; the provision of means for detecting breast cancer that can complement mammography and increase the predictive value; the provision of methods that can provide an estimation of prognosis; the provision of markers that will allow the targeting of therapy; and the provision of compositions for stimulating a cellular and humoral immune response against the tumor.
Brief Description of the Drawings Figure 1 illustrates the strategy used to isolate the full length mammaglobin cDNA including the Rapid amplification of cDNA Ends (RACE) Polymerase Chain Reaction (PCR) technique and subsequent subcloning into vectors pGEM7Z and pCEV27.
Figure 2 illustrates the human cDNA sequence (SEQ ID NO:1), (nucleotides numbered above) and the amino acid sequence of the encoded mammary-specific protein, mammaglobin (SEQ ID NO:2)(amino acids numbered below), the solid bar WO 00/18783 PCT/US99/22616 6 indicating the 403 bp fragment (SEQ ID NO:5) isolated by the RACE PCR method and the open bar indicating the 206 bp DEST002 sequence (SEQ ID NO:6); Figure 3 illustrates the amino acid sequence of the mammary-specific protein, mammaglobin (hMAM), (SEQ ID NO:2) compared to rat prostatic steroid binding protein subunit C3 (rPSC3)(SEQ ID NO:7) and human clara cell 10 kD protein ID NO:8) with identities marked by bold letters and double lines and structurally similar amino acids marked by single lines; Figure 4 illustrates (FIG. 4A) the Northern blot analysis of hybridization of the human cDNA sequence encoding the mammary-specific protein, mammaglobin (hMAM), to mRNA expressed by tissues from breast neoplasia, normal breast and other adult tissues and (FIG. 4B) the analysis of RT/PCR amplified samples of tissues from breast neoplasia, normal breast and other adult tissues; Figure 5 illustrates the translation of the mammary-specific cDNA sequence in an in vitro rabbit reticulocyte lysate assay system; Figure 6 illustrates Northern blot hybridization with the cDNA encoding mammaglobin showing detection of mRNA in tumor 2410, in tumors from three of eight other patients (shown in bold), and to a lesser extent, in normal breast tissue (shown in italics), and comparing in two cases (the four lanes on the right) mammaglobin mRNA expression in tumor tissue and patient matched normal tissue; Figure 7 illustrates the Western blot analysis using polyclonal antibody to the mammaglobin C-terminus (SEQ ID NO: 14) of the conditioned medium and cell lysate from MDA-MB-415 breast tumor cells in the absence and presence of the immunizing peptide showing detection of the precursor and secreted forms of mammaglobin protein in the cell medium and cell lysate, respectively; Figure 8 illustrates the Western blot analysis using the anti-mammaglobin polyclonal antibody of the conditioned medium and cell lysate from MDA- MB-415 breast tumor cells grown in the absence and presence of tunicamycin, which blocks glycosylation, showing the lack of detectable mammaglobin protein in the lysate or medium of cells in which N-linked glycosylation is inhibited; Figure 9 illustrates the Western blot analysis of cell lysates from human breast tumor cells showing detection of the precursor mammaglobin protein using the anti- WO 00/18783 PCT/US99/22616 7 mammaglobin polyclonal antibody and goat anti-rabbit antibody visualized by enzyme-linked chemiluminescence; Figure 10 illustrates the Western blot analysis using the anti-mammaglobin polyclonal antibody of fluid secretions from human breast during pregnancy and postpartum showing detection of the secreted mammaglobin protein in proliferating mammary gland; Figure 11A illustrates in color a paraffin-fixed section of breast cancer cells from a patient specimen immunohistochemically stained using the anti-mammaglobin polyclonal antibody and goat anti-rabbit antibody tagged with horseradish peroxidase and DAB as substrate showing a brown staining of cells expressing the mammaglobin protein; Figure 11B illustrates in black and white a paraffin-fixed section of breast cancer cell from a patient specimen immunohistochemically stained using the antimammaglobin polyclonal antibody and goat anti-rabbit antibody tagged with horseradish peroxidase and DAB as substrate wherein the brown staining of cells expressing the mammaglobin protein is indicated; Figure 12 illustrates mammaglobin immunoreactivity in tissue sections from the same specimens of (FIGS. 12A, 12B) pure ductal carcinoma in situ (DCIS), (FIGS. 12C, 12 D) well differentiated ductal carcinoma, and (FIGS. 12E, 12F) poorly differentiated ductal carcinoma which were immunohistochemically stained with (FIGS. 12A, 12C, 12E) mammaglobin antiserum or (FIGS. 12B, 12D, 12F) preimmune antiserum; Figure 13 shows a photograph of a northern blot of RNA from lymph node specimens containing histologically documented metastases from primary breast tumors (lanes 1-20, 27), squamous cell tumors of the head and neck (lanes 21, 23, 24), endometrial cancer (lane 22), adenocarcinoma of the colon (lane 25), billiary carcinoma (land 26), and adenocarcinoma of the lung (lane 28) and, as negative controls, lymph node biopsies from patients without any known malignancy (lanes 29-33) and as a positive control, a specimen from normal breast tissue (lane 34), and hybridized with the mammaglobin cDNA (top panels) or a keratin cDNA (bottom panels); and WO 00/18783 PCTIUS99/22616 8 Figure 14 shows a photograph of a Southern blot of RT-PCR products of RNA from patients with metastatic breast cancer (CA) or normal donors (NL) obtained from peripheral stem cell collections and probed with the mammaglobin cDNA probe.
Description of the Preferred Embodiments: One aspect of the present invention is based upon the identification and sequencing of the cDNA identified as SEQ ID NO:1 which encodes a mammaryspecific secretory protein, mammaglobin, identified by SEQ ID NO:2 (FIG As described below, the full length mammaglobin cDNA was isolated starting from tumor cell mRNA that was reverse transcribed, amplified using the technique of PCR and subcloned into expression vectors. In addition, the protein, mammaglobin, encoded by the cDNA was identified and characterized.
Using the anonymous sequence tag previously designated DEST002, it was demonstrated that the corresponding gene product, which was up until now unknown but herein identified as mammaglobin, is particularly abundant in the breast cancer tumor cell line MDA-MB-415. To isolate the full length mammaglobin cDNA, the mRNA was reverse transcribed from this cell line and cloned using the RACE PCR technique (Edwards et al. Nucleic Acids Research 19:5227-32, 1991). This technique is based upon the strategy of ligation of single-stranded oligodeoxyribonucleotide to the 3' end of single-stranded cDNA. The method by which the mammaglobin cDNA was isolated is represented schematically in FIG 1.
The full length 503 bp cDNA sequence (SEQ ID NO: 1) was deduced from the sequence information obtained from the 403 bp fragment (SEQ ID NO:5) (FIG 2) isolated by this technique along with sequence information previously obtained from the corresponding DEST sequence (DEST002, SEQ ID NO:6) (FIG 2) in our earlier study (Watson and Fleming, supra). Within the 503 bp cDNA is a 279 bp open reading frame (SEQ ID NO:15) which encodes a polypeptide of 93 amino acids (SEQ ID NO:2) (FIG 2) and predicted molecular mass of 10.5kD. The initial methionine of this open reading frame is within a near-perfect Kozak consensus sequence (Kozak, Cell 22:7-8, 1980). The 60 bp upstream of this sequence contain no other in-frame methionines or translational stops. The 3' untranslated sequence of the cDNA constitutes 163 bp and contains a polyadenylation signal, AATAAA, 12 bp upstream WO 00/18783 PCT[US99/22616 9 of the priming site of the original DEST002 sequence. These data indicate that the full length mammaglobin cDNA has been isolated. The first 19 residues of the encoded polypetide predict a hydrophobic peptide signal sequence and residues 53-55 and 68-70 are consensus N-linked glycosylation sites, indicating that mammaglobin is a secreted glycoprotein.
A search for DNA sequences similar to the mammaglobin cDNA sequence in Genbank using the BLAST algorithm (Benson et al., Nucl Acid Res21:2963-2965, 1993; Altschul et al, JMol Biol 215:403-410, 1990), identified no obvious DNA sequence homologies. Thus, mammaglobin cDNA is believed to be a novel, heretofore unknown DNA sequence.
A search of other polypeptides for sequences related to mammaglobin revealed an amino acid sequence homology between mammaglobin and other polypeptides. Mammaglobin exhibited 42% amino acid identity (58% including conservative substitutions) with rat prostatic steroid binding protein (prostatein) subunit C3 (rPSC3) (FIG 3) (SEQ ID NO:7). Rat prostatic steroid binding protein is a major secretory protein in the rat ventral prostate consisting of a tetrameric protein composed of two different dimeric subunits; C3/C1 and C3/C2 (Parker et al., Ann N Y AcadSci 438:115-124; Parker et al., JSteroid Biochem 20:67-71, 1984). The Cl, C2, and C3 genes all encode approximately 6 kD secretory proteins and are thought to have arisen from gene duplication, but while the Cl and C2 genes show strong homology to each other, they are much less similar to the C3 gene. Correspondingly, mammaglobin shows no sequence homology with the Cl or C2 proteins.
As noted above, prostatic steroid binding protein (prostatein) is the major secretory protein in the rat ventral prostate and its expression is regulated by androgenic steroids (Parker et al, Ann N YAcad Sci 438:115-24, 1984; Parker et al, J Steroid Biochem 20:67-71, 1984). Another protein, human estramustin-binding protein (hEMBP) has been reported to be expressed in human prostate, human breast cancer and human malignant melanoma. (Bjork et al, Cancer Res 42:1935-1942, 1982; Bjork et al, Anticancer Res 11:1173-82, 1991). Human estramustin-binding protein is immunochemically similar to rat estramustin-binding protein, which has been postulated to be identical to rat steroid-binding protein, prostatein. As noted above, the amino acid sequence of mammaglobin exhibited 42% amino acid identity WO 00/18783 PCT/US99/22616 and 58% homology including conservative substitutions with the C3 subunit of prostatein. Thus it is possible that mammaglobin could be in some way related to hEMBP. However, while both prostatein and hEMBP are detected in the prostate gland, mammaglobin mRNA is completely absent in this tissue. Hence, mammaglobin is neither the same protein nor a subunit of hEMBP and, furthermore, the sequence of hEMBP has not been determined so that it is not known whether there is even any similarity of mammaglobin with some fragment or subunit of hEMBP.
Although recent reports have demonstrated the rPSC3 promoter fused to T antigen produces both prostatic and mammary carcinomas in transgenic mice (Maroulakou et al., Proc NatAcadSci U.S. 91:11236-11240, 1994; Sandmoller et al, Oncogene 9:2805-2815, 1994), the true biological function of this protein is unknown.
Furthermore, notwithstanding the hypothesized relationship of rat prostatic steroid binding protein to human EMBP, no human polypeptide or human gene corresponding to rPSC3 has been identified. Thus, mammaglobin and the cDNA encoding mammaglobin represent novel sequences heretofore unknown.
Using manual alignment with other sequences that had less significant BLAST scores with both mammaglobin and rPSC3 protein sequences, we identified other homologies with human clara cell 10kD protein (hCC10) (SEQ ID NO:8) (Peri et al, J Clin Invest 92:2099-2109, 1993) (FIG 3) and, in addition, with rabbit and mouse uteroglobin proteins (Miele et al., Endocrine Rev 8:474-90, 1987; Cato and Beato, Anticancer Res 5:65-72, 1985; Miele et al., JEndocrinol Invest 17:679-692, 1994).
These homologies, depending on species, were 26% identity or 40% including conservative substitutions. In particular, a number of amino acids were perfectly conserved among all proteins, including Cys-3 and Cys-69 which are known to play a role in disulfide bond formation between uteroglobin subunits (see below). These homologies suggest that mammaglobin is a novel member of a small family of proteins that are secreted by epithelial cells (Miele et al, 1994, supra).
The hCC10 gene is the human homologue of rabbit and mouse uteroglobin genes (Peri et al, J Clin Invest 92:2099-2109, 1993). Uteroglobin was originally characterized as a secretory protein in rabbit uterus, but has since been found in other epithelial organs including lung, breast and prostate. Unlike rat prostatein, uteroglobin is a homodimeric protein coupled by two disulfide linkages at the WO 00/18783 PCT[US99/22616 11 conserved residues Cys-2 and Cys-69 (Miele et al, 1994, supra). Although uteroglobin gene transcription is regulated by steroid hormones, the ability of the protein itself to bind progesterone or other steroid hormones is controversial and again, the true biological function of this protein is unknown (Miele et al., 1994, supra).
Mammaglobin expression is restricted to the mammary gland. This is in contrast to the observation that rPSC3 is expressed in rat ventral prostate (Parker et al., Ann N YAcadSci 438:115-1124, 1984), and the expression of hCC1O/uteroglobin in numerous tissues including lung, uterus, prostate, and breast (Miele et al., 1987, supra; Cato and Beato, supra; Miele et al., 1994 supra). Because of the sequence homology between mammaglobin and these proteins, we determined the pattern of tissue specific expression.
The 500 bp mammaglobin mRNA was easily detected in tumor specimen 2410 (the tissue from which this original sequence tag was isolated) and to a much less extent in normal human breast tissue (FIG 4A). Mammaglobin mRNA could not be detected in the immortalized breast epithelial cell line B5-589. Expression of mammaglobin was also undetectable in human uterus and lung, two sites of uteroglobin expression.
Amplification using RT/PCR detected mammaglobin mRNA in both tumor 2410 and normal breast tissue, but not in 15 other tissues surveyed, including tissues that normally express rPSC3 and uteroglobin (lung, uterus, prostate), hormonally responsive and steroidogenic tissues (ovary, testis, placenta), and other secretory epithelial organs (colon) (FIG 4B). Therefore, the expression of mammaglobin mRNA is relatively specific for mammary tissue.
To unequivocally demonstrate the breast-specific nature of mammaglobin expression, the full-length mammaglobin cDNA was used to probe for mammaglobin mRNA in a more extensive and quantitative panel of polyA-selected mRNAs from pooled populations of adult and fetal human tissues as described below in Example 2A. Mammaglobin mRNA expression was completely absent in other closesly related apocrine glands such as the salivary gland and was also undetectable in peripheral leukocytes, lymph node, and bone marrow. Apart from the mammary gland, mammaglobin mRNA was not detected in any other of the 43 adult or seven fetal WO 00/18783 PCT/US99/22616 12 tissues surveyed. This confirms that mammaglobin gene expression is likely to be a very specific marker for breast cancer.
Based on the studies in this report, mammaglobin is a relatively mammaryspecific protein. Two other genes known to be overexpressed in breast carcinoma are erb-B and cyclin D (Jardines et al, Pathobiology 61:268-282, 1994; Keyomars and Pardee, Proc Nat Acad Sci U.S. 90:1112-1116, 1993). Unlike the overexpression of erb-B or cyclin D, the overexpression of mammaglobin may reflect a more specific alteration of the mammary epithelial cell rather than a general increased growth potential or mitotic rate. As such, appearance of mammaglobin gene dysregulation may have more specific import for the therapeutic vulnerability or clinical course of a tumor.
As reported in U.S. Patent No. 5,668,267, overexpression of mammaglobin mRNA was detected by northern blot hybridization in the 2410 tumor specimen as well as 4 of 15 stage 1 primary breast carcinomas of differing histological types. This percentage is comparable to the prevalence of other genetic alterations such as erb-B amplification and p53 mutation (Slamon et al. Sci 244:707-712, 1989; Thor et al, JNat'l Cancer Inst 84:845-855, 1992). Furthermore, because we have restricted our analysis to stage I tumors, overexpression of mammaglobin would actually be more prevalent than any other genetic alteration reported in this subgroup of tumors (Alllerd et al, JNat'l Cancer Inst 85:200-206, 1993). These data suggest that overexpression of mammaglobin is not unique to a single tumor specimen and is, in fact, relatively frequent among primary breast tumors. Furthermore, the fact that all tumors examined were stage I suggests that this dysregulation occurs relatively early in the progression of breast neoplasia.
Mammaglobin expression could not be detected in normal lymph nodes or peripheral lymphocytes at the level of sensitivity afforded by a single step RT/PCR assay. However, as reported below, mammaglobin mRNA was detected in over of lymph nodes and in 60% of peripheral blood stem cell collections (PBSCs) from patients with metastatic breast cancer. These results indicate that analysis of mammaglobin transcripts in peripheral lymph nodes and blood stem cells may be useful for detecting occult breast cancer metastases, as has been suggested for other epithelial specific genes (Schoenfeld et al., Cancer Res 54:2986-2990, 1994).
WO 00/18783 PCT/US99/22616 13 To demonstrate that the mammaglobin cDNA encoded a translatable protein, the cDNA clone was used in an in vitro translation assay. Figure 5 shows the protein product from a rabbit reticulocyte lysate programmed with the mammaglobin cDNA.
An approximately 6 kD protein is generated using the mammaglobin cDNA. The apparent molecular weight is smaller than that predicted from conceptual translation of the open reading frame, but this finding is commonly observed with rabbit and human uteroglobin translation products as well.
To examine the prevalence of mammaglobin protein expression in breast cancer, rabbit polyclonal, anti-mammaglobin antibody was generated against a peptide corresponding to the C-terminal mammaglobin protein sequence and used to examine 100 primary breast tumors of multiple grades and histological types for mammaglobin protein expression by immunohistochemical analysis. As summarized in Table 1 below, over 80% of these tumors were strongly immunopositive for mammaglobin protein and staining was independent of tumor grade. This result indicates that detection of mammaglobin protein in clinical samples can be used as a sensitive and specific marker for primary breast cancer.
Because Applicants believe mammaglobin is a secreted protein, its presence would be expected to be detectable in sera from patients whose tumors overexpress this gene product. As such, mammaglobin is likely to be as clinically useful as prostate specific antigen (PSA) and other solid tumor markers for managing patients with breast cancer (Tumor markers in diagnostic pathology, Clin Lab Med 10:1-250, 1990).
The identification of mammaglobin as a breast cancer marker provides the basis for another aspect of the present invention, which involves methods for detecting the presence of breast cancer in a patient. The term "detection" as used herein in the context of detection of breast neoplastic disease is intended to be a comprising aspect of the determining of the presence of breast cancer in a patient, the distinguishing of breast cancer from other diseases, the estimation of prognosis in terms of probable outcome of the disease and prospect for recovery, the monitoring of the disease status or the recurrence of the disease, the determining of a preferred therapeutic regimen for the patient and the targeting of antitumor therapy.
WO 00/18783 PCTIUS99/22616 14 One method for detecting breast cancer comprises hybridizing a polynucleotide to mRNA from breast neoplasia cells. The polynucleotide comprises the complement of SEQ ID NO: 15 or a derivative of the complement of SEQ ID As used herein, a polynucleotide includes DNA and/or RNA and thus the nucleotide sequences recited in the Sequence Listing as DNA sequences also include the identical RNA sequences with uracil substituted for thymine residues. A derivative of a nucleotide sequence has sufficient sequence identity to the sequence from which it is derived to specifically hybridize to mammaglobin mRNA from breast neoplasia cells under the same stringency conditions that the sequence from which it is derived specifically hybridizes to the mammaglobin mRNA from breast neoplasia cells. The derived nucleotide sequence is not necessarily physically derived from the nucleotide sequence, but may be generated in any manner including for example, chemical synthesis or DNA replication or reverse transcription or transcription.
Preferred derivative nucleotide sequences include fragments of the complement of SEQ ID NO: 15 and sequences identical to the complement of an allelic variant of the mammaglobin coding sequence set forth in SEQ ID NO: To detect the presence of mRNA encoding mammaglobin in a detection system for breast cancer, a sample is obtained from a patient. The sample can be a tissue biopsy sample or a sample of blood, plasma, serum or the like. The sample may be treated to extract the nucleic acids contained therein. Preferably, the resulting nucleic acid from the sample is subjected to gel electrophoresis or other size separation techniques.
Detection involves contacting the nucleic acids and in particular the mRNA of the sample with the polynucleotide probe to form hybridization duplexes. The term "probe" refers to a structure comprised of a polynucleotide which forms a hybrid structure with a target sequence, due to complementarily of probe sequence with a sequence in the target region.
Detection of the resulting duplex can be accomplished by any known methodology. The hybridization duplex is usually accomplished by the use of labeled probes. Alternatively, the probe may be unlabeled, but may be detectable by specific binding with a ligand which is labeled, either directly or indirectly. Suitable labels and methods for labeling probes and ligands are known in the art, and include, for WO 00/18783 PCT[US99/22616 example, radioactive labels which may be incorporated by known methods nick translation or kinasing), biotin, fluorescent groups, chemiluminescent groups dioxetanes, particularly triggered dioxetanes), enzymes, antibodies, and the like.
When probing with a mammaloglobin cDNA, high stringency conditions can be used in order to prevent false positives. When using a probe containing a sequence derived from the complement of the mammaglobin coding sequence, less stringent conditions can be used. The stringency of hybridization is determined by a number of factors during hybridization and during the washing procedure, including temperature, ionic strength, length of time and concentration of formamide. These factors are outlined in, for example, Sambrook et al. (Molecular Cloning: A Laboratory Manual, 2d ed., 1989).
In order to increase the sensitivity of detection of mammaglobin mRNA in a sample, the technique of reverse transcription/polymerization chain reaction (RT/PCR) can be used to amplify cDNA transcribed from mRNA encoding mammaglobin. The method of RT/PCR is well known in the art (for example, see Watson and Fleming, supra). Oligonucleotides useful as the amplification primers comprise SEQ ID NO:3 and SEQ ID NO:4. Preferably, the mammaglobin forward amplification primer consists of 5'-AGCACTGCTACGCAGGCTCT-3' (SEQ ID NO: 16) and the mammaglobin reverse amplification primer consists of ATAAGAAAGAGAAGGTGTGG-3' (SEQ ID NO:4).
Alternatively, a mammaglobin target sequence in the reverse transcribed cDNA can be amplified and detected using any other known methodology such as ligase chain reaction methods, including gap LCR (G-LCR) and other variations, or self-sustained sequence replication (3SR) and its various modifications. In addition, the mammaglobin mRNA can be detected directly by asymmetric gap LCR (AG- LCR). See, Leckie et al., "Infectious Disease Testing by Ligase Chain Reaction" in Molecular Biology and Biotechnology, R. A. Myers, ed., pp. 463-466, VCH Publishers, 1995.
In another embodiment of the present invention, the mammaglobin cDNA sequence or derivative thereof can be used to characterize any alteration of the mammaglobin gene gene rearrangement, gene amplification, or gene deletion) in a specimen from a breast-cancer patient. This provides a method whereby patient WO 00/18783 PCT/US99/22616 16 specimens or samples, which do not contain intact mRNA, can still be examined for changes in gene structure.
In one application of this technique, the mammaglobin cDNA sequence or derivative thereof is hybridized to patient genomic DNA that has been isolated from a patient's tumor, normal tissue, or lymphocytes and digested with one or more restriction endonucleases. Using the Southern blot protocol, which is well known in the art, this assay determines whether a patient or a patient's breast tumor has a mammaglobin gene, which was deleted, rearranged, or amplified. Detection of these changes can then provide important information useful for predicting prognosis and for patient management.
In a second application of this technique, one or more pairs of oligonucleotide primers based on the mammaglobin cDNA sequence and complement thereof could be used in the polymerase chain reaction to amplify segments of the mammaglobin gene from a patient sample. Analysis of the resulting PCR products indicate whether a particular segment of the mammaglobin gene is deleted or rearranged. Such information is useful for prognosis and patient management.
Another method for detecting breast cancer comprises detecting the presence of the precursor and/or secreted forms of the mammaglobin polypeptide in a sample obtained from a patient. Any method known in the art for detecting proteins can be used. Such methods include, but are not limited to immunodiffusion, immunoelectrophoresis, immunochemical methods, binder-ligand assays, immunohistochemical techniques, agglutination and complement assays. (for example see Basic and Clinical Immunology, Sites and Terr, eds., Appleton Lange, Norwalk, Conn. pp 217-262, 1991). Preferred are binder-ligand immunoassay methods including reacting antibodies with an epitope or epitopes of mammaglobin and competitively displacing a labeled mammaglobin polypeptide or derivative thereof.
As used herein, the term "mammaglobin polypeptide" embraces naturally occurring mammaglobin, including nonglycosylated and glycosylated precursor forms and the glycosylated secreted form, derivatives and fragments thereof. By naturally occurring is meant a polypeptide that can be isolated from a source in nature, e.g., from normal and/or diseased organisms, and that has not been intentionally modified WO 00/18783 PCT/US99/22616 17 by man. Naturally-occurring mammaglobin polypeptides identified herein include a precursor form which comprises SEQ ID NO:2 and a secreted form comprising SEQ ID NO:17 (amino acids 20-93 of SEQ ID NO:2). Allelic variants of SEQ ID NO:2 are also intended to be included in the scope of naturally-occurring mammaglobin polypeptides.
A derivative of a mammaglobin polypeptide is intended to refer to polypeptides which are comprised of a segment of at least 10 amino acids that has substantial identity to a portion of naturally occurring mammaglobin. The segment having substantial identity is preferably at least about 20 amino acids, more preferably at least about 50 amino acids, and most preferably at least about 75 amino acids. Two polypeptides have substantial identity when upon optimal alignment by sequence alignment programs such as BLAST using default settings for gap penalties and other parameters, they share at least 80% sequence identity, preferably at least sequence identity, more preferably at least 95% sequence identity, most preferably 99% sequence identity. Preferably, residue positions which are not identical differ by conservative amino acid substitutions.
Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulfur-containing side chains is cysteine and methionine. Preferred conservative amino acid substitution groups are: valineleucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine-glutamine.
A derivative mammaglobin polypeptide will preferably cross-react with an anti-mammaglobin antibody, monoclonal or polyclonal, which is specific for naturally occurring mammaglobin or fragments thereof.
As used herein the terms "fragment" and "peptide" refer to a mammaglobin polypeptide having an amino acid sequence identical to the amino acid sequence WO 00/18783 PCT[US99/22616 18 deduced from a full-length mammaglobin cDNA SEQ ID NO:1), but that has an amino-terminal and/or carboxy-terminal deletion. Typically, mammaglobin fragments or peptides are at least 3 amino acids long. Preferably a mammaglobin fragment or peptide is at least 6 amino acid residues in length, more preferably about 12 amino acid residues in length, even more preferably about 25 amino acid residues in length, and most preferably 50 amino acid residues or greater.
Numerous competitive and non-competitive protein binding immunoassays are well known in the art. Antibodies employed in such assays may be unlabeled, for example as used in agglutination tests, or labeled for use in a wide variety of assay methods. Labels that can be used include radionuclides, enzymes, fluorescers, chemiluminescers, enzyme substrates or co-factors, enzyme inhibitors, particles, dyes and the like for use in radioimmunoassay (RIA), enzyme immunoassays, e.g., enzyme-linked immunosorbent assay (ELISA), fluorescent immunoassays and the like.
Polyclonal or monoclonal antibodies to a mammaglobin polypeptide comprising a B cell epitope can be made for use in immunoassays by any of a number of methods known in the art. As used herein, the term "B cell epitope" refers to an antigenic determinant of a mammaglobin polypeptide. The B cell epitope could comprise 3 amino acids in a spatial conformation which is unique to the epitope.
Generally, a B cell epitope consists of at least 5 such amino acids. Methods of determining the spatial conformation of amino acids are known in the art, and include, for example, x-ray crystallography and 2 dimensional nuclear magnetic resonance.
One approach for preparing antibodies to a protein is the selection and preparation of an amino acid sequence of all or part of the protein, chemically synthesizing the sequence and injecting it into an appropriate animal, usually a rabbit or a mouse.
Methods for preparation of a mammaglobin polypeptide include, but are not limited to chemical synthesis, recombinant DNA techniques or isolation from biological samples. Chemical synthesis of a peptide comprising an epitope can be performed, for example, by the classical Merrifeld method of solid phase peptide synthesis (Merrifeld, JAm Chem Soc 85:2149, 1963) or the FMOC strategy on a WO 00/18783 PCT/US99/22616 19 Rapid Automated Multiple Peptide Synthesis system (DuPont Company, Wilmington, DE) (Caprino and Han, J Org Chem 37:3404, 1972).
Polyclonal antibodies can be prepared by immunizing rabbits by injecting antigen into the popliteal lymph nodes followed by subsequent boosts at two week intervals with intraperitoneal injection of antigen. The animals are bled and sera assayed against purified mammaglobin protein, usually by ELISA. Monoclonal antibodies can be prepared after the method of Milstein and Kohler by fusing splenocytes from immunized mice with continuously replicating tumor cells such as myeloma or lymphoma cells. (Milstein and Kohler Nature 256:495-497, 1975; Gulfre and Milstein, Methods in Enzymology: Immunochemical Techniques 73:1-46, Langone and Banatis eds., Academic Press, 1981). The hybridoma cells so formed are then cloned by limiting dilution methods and supernates assayed for antibody production by ELISA or RIA.
Thus prepared polyclonal or monoclonal antibodies to mammaglobin may be used to isolate and purify precursor and secreted forms of mammaglobin from cells expressing mammaglobin. For example, as shown below, a polyclonal antibody generated against the 16 C-terminal amino acids predicted from mammaglobin cDNA (Glu-Val-Phe-Met-Gln-Leu-Ile-Tyr-Asp--Sr-Ser-Leu-Cys-Asp-Leu-Phe, SEQ ID NO:14) binds to precursor and secreted forms of mammaglobin, as well as to mammaglobin that has been synthesized in an in vitro translation system. Isolation of mammaglobin using an anti-mammaglobin antibody may be accomplished using procedures well-known in the art, such as affinity chromatography.
The unique ability of antibodies to recognize and specifically bind to target antigens expressed by a tumor cell provides an approach for the treatment of cancer.
(For review see LoBuglio and Saleh, Am J Med Sci 304:214-224, 1992; Bagshawe, Adv Pharmacol 24:99-121, 1993). Thus, another aspect of the present invention provides for a method for preventing the onset and treating breast cancer in an animal based upon the use of antibodies to mammaglobin, which has been discovered to be overexpressed by breast cancer cells.
Specific antibodies to mammaglobin, either polyclonal or monoclonal, are produced by any method known in the art. For example, murine or human monoclonal antibodies can be produced by hybridoma technology. Alternatively, WO 00/18783 PCT/US99/22616 mammaglobin, or an immunologically active derivative or fragment thereof, or an anti-idiotypic antibody, or fragment thereof, can be administered to an animal to elicit B cell production of antibodies capable of recognizing the mammaglobin-expressing cells.
The antibodies so produced or fragments thereof are labeled with one or more oncolytic substances such as radionuclides, toxins, or cytotoxic drugs and administered to a patient suspected of having breast cancer. The binding of the labeled antibody to the mammaglobin being overexpressed by the breast cancer cell will cause the death of the cancer cell.
Any of a variety of oncolytic substances known in the art can be used to produce such labeled antibodies. For example, immunotoxins can be made by coupling plant and bacterial toxins to antibodies. Such toxins include, for example, ricin, diphtheria toxin and Pseudomonas exotoxin A. Drug-antibody conjugates can also be made in which chemotherapeutic agents are linked to the antibody.
Chemotherapeutic agents suitable for such use include, for example, tomoxifen, doxorubicin, methotrexate, chlorambucil, Vinca alkaloids, and mitomycin. In addition, radioimmunoconjugates can be made in which a radionuclide is stably linked to the antibody. Radionuclides suitable for making radioimmunoconjugates include, for example, B-emmitters such as 131I, 86Re, 6Cu, 90Y and 4 7 Sc; cemitters such as 2 1 At, 212 Bi and 21 2 Pb; auger electron emitters such as 125I and 77Br; and fissionable nuclides such as l1B.
The finding that a significant percentage of breast tumors express mammaglobin protein is the basis for another aspect of the invention, which involves the activation of mammaglobin-specific B and/or T cell lymphocytes (Tc) with mammaglobin antigens. Accordingly, the invention provides mammaglobin B cell antigens and Tc cell antigens; vaccines comprising at least one B cell mammaglobin antigen and/or at least one Tc mammaglobin antigen for inducing antibody- and/or cell-mediated immune responses against mammaglobin-expressing tumors, and methods for treating a breast cancer patient with a mammaglobin-expressing tumor.
One method according to the invention comprises administering to the patient activated mammaglobin-specific lymphocytes. Another method comprises administering to the patient a mammaglobin-specific vaccine.
WO 00/18783 PCTIS99/22616 21 As used herein, "mammaglobin antigen" includes naturally occurring mammaglobin polypeptides, derivatives, and fragments thereof which contain a B cell or Tc cell epitope recognized by mammaglobin-specific B cells or Tc cells.
A mammaglobin B cell antigen comprises a mammaglobin-specific B cell epitope and a TH cell epitope. The term "B-cell epitope" refers to any antigen, hapten, epitope or antigenic determinant which is recognized by anti-mammaglobin immunoglobulin receptors on B cells and is capable of eliciting the production of antibodies with appropriate help from TH cells when administered to an animal. The B cell epitope comprises an amino acid sequence of at least 4 amino acids.
Preferably, the B cell epitope is between at least 6 and 25 amino acids in length and more preferably is between about 15 and 22 amino acids in length. The comprising amino acid sequence of the B cell epitope may be identical or substantially identical to a continuous amino acid sequence in a fragment of naturally occurring mammaglobin. Alternatively, the comprising amino acid sequence of a B cell epitope is identical to or substantially identical to a discontinuous amino acid sequence representing an assembled topographic determinant of mammaglobin.
The term "TH cell epitope" refers to any antigenic determinant recognized by T helper cells through association with MHC class II molecules. The activation ofT helper cells induces differentiation of resting mammaglobin-specific B cells into higher affinity IgG-secreting cells, i.e, induces a secondary antibody response. The preparation and use of immunogenic peptides containing B and TH cell determinants to produce higher titres of specific antibody-producing B cells through T cell help is known in the art, see, Cheronis et la., U.S. Patent No. 5.573,916, Denton, et la., Cancer Letters 70:143-150 (1993), Borras-Cuesta et al., Eur. J. Immunol. 17, 1213- 1215 (1987), and Good et al., Science 235:1059-1062 (1987). The TH cell epitope may comprise an amino acid sequence from mammaglobin or a heterologous protein.
For example, Denton et al. describe the induction of antibody responses to mucins, which are complex glycoproteins expressed in secretory epithelia and associated with breast and other carcinomas, in mice immunized with a synthetic peptide containing a B cell determinant region from the core of MUC- 1 mucin linked to sequence 111-120 of influenza haemagglutinin A/X-31, a known helper T cell-determinant. The TH cell epitope comprises an amino acid sequence of between about 6 to about 20 amino acid WO 00/18783 PCTIUS99/22616 22 residues, preferably between about 8 residues and 18 residues, even more preferably between 9 residues and 15 residues.
A mammaglobin Tc cell antigen comprises a Tc cell epitope and a MHC class I agretope. The term "Tc cell epitope" means any antigen, epitope or antigenic determinant which is recognized by mammaglobin-specific Tc cells when presented by a MHC class I molecule on the surface of an antigen presenting cell. The term "MHC class I agretope" refers to any amino acid sequence recognized by a MHC class I molecule that allows the mammaglobin antigen to be presented to a mammaglobin-specific Tc cell by the MHC class I molecule on an antigen presenting cell (APC). The Tc cell epitope and MHC class I agretope are contained within an amino acid sequence of between about 6 to about 11 amino acids that is identical or substantially identical to the amino acid sequence of a fragment of naturally occurring mammaglobin. Preferably, the sequence is 8 or 9 amino acids in length.
Methods for identifying B and Tc cell epitopes for a protein antigen are known in the art. For example, the capacity of isolated mammaglobin-specific B cells or mammaglobin-specific Tc cells to respond to overlapping synthetic peptides spanning secreted mammaglobin may be determined using standard immunobiology techniques. Those peptides identified as antigenic may then be modified one or a few amino acids at a time to optimize their ability to stimulate mammaglobin-specific B or T cells.
B cell epitopes can also be mapped using commercially available epitope mapping kits which involve the screening of random peptides bound at the C terminus to polyethylene multipin supports, Cambridge Research Biochemicals.
Alternatively, the predicted mammaglobin amino acid sequence may be searched for sequences that conform to known binding motifs of MHC class I or MHC class II molecules. See e.g, Hill et al., Nature 360:434 (1992), Pamer et al., Nature 360:852 (1992) and Hammer et al., J. Exp. Med. 176:1007 (1992), and Falk et al., Nature 351:290-296 (1991). For example, antigenic peptides recognizable by breast tumor-specific CTLs may be identified by searching the mammaglobin amino acid sequence for HLA-A2-binding peptides as described by Peoples et al., Proc.
Natl. Acad. Sci. 92:432-436 (1995). The choice of HLA-A2 as the antigen presenting molecule is appropriate where the patient expresses HLA-A2 (approximately 50% of WO 00/18783 PCTIUS99/2616 23 Caucasians express HLA-A2). The predicted HLA-A2 binding peptides can be synthesized and tested for antigenicity by loading the synthetic peptides onto the T2 cell line, a human T-cell/B-cell fusion product containing a defect in antigen presentation such that HLA-A2 molecules on the surface of T2 cells can be effectively loaded with exogenous HLA-A2 binding peptides (Henderson, et al, Science 255:1264-1266 (1992)). A standard cytotoxicity assay is then carried out which comprises incubating the peptide-loaded T2 cells with breast-specific CTLs derived from tumor infiltrating lymphocytes (TILs) isolated from a mammaglobinexpressing breast tumor, see Peoples et al., pages 432-433 and Toso et al., Cancer Research 56:16-20 (1996).
Antigenic mammaglobin peptides containing Tc cell epitopes may also be identified by acid-eluting endogenous peptides presented by HLA class I molecules on the tumor cell surface. (See, e.g.,Peoples et al., supra, p. 433). The eluted peptides may be separated by any number of techniques known in the art, including HPLC fractionation. The different peptide fractions are loaded onto T2 cells and the loaded T2 cells are incubated with breast-tumor specific CTLs to determine which peptides are recognized by the CTLs using standard immunobiology techniques.
One use of a mammaglobin antigen according to the invention is in adoptive immunotherapy. This therapy involves in vitro activation and expansion by a mammaglobin antigen of anti-mammaglobin antibody-producing B cells and/or mammaglobin-specific cytotoxic T lymphocytes (CTLs) isolated from a patient with a mammaglobin-expressing tumor. The method may also be practiced with a composition comprising both mammaglobin B cell and Tc cell antigens. The activated lymphocytes are then introduced back into the patient for adoptive immunotherapy.
A mammaglobin antigen according to the invention is also useful as a component of a mammaglobin-specific vaccine. The vaccine comprises an immunogenically-stimulatory amount of a mammaglobin antigen. As used herein, an immunostimulatory amount refers to that amount of antigen that is able to stimulate the desired immune response in the recipient for the amelioration, or treatment, of breast cancer. This amount may be determined empirically by standard procedures, well known to those of ordinary skill in the art, without undue experimentation.
WO 00/18783 PCT/US99/22616 24 The antigen may be provided in any one of a number of vaccine formulations which are designed to induce the desired type of immune response, antibody and/or cell mediated. Such formulations are known in the art. See, A.
Lanzavecchia, Science 260:937-944 (1993) and U.S. Patent No. 5,585,103 to Raychandhuri. Examples of vaccine formulations used to stimulate immune responses include pharmaceutically acceptable adjuvants such as aluminum salts; emulsions of squalene or squalane and muramyl dipeptide; liposomes; and a composition comprising a stabilizing detergent, a micelle-forming agent, and a biodegradable and biocompatible oil (Raychandhuri, supra).
A mammaglobin-specific vaccine may also comprise a carrier cell loaded with a mammaglobin antigen. Preferably, the carrier cell is prepared from autologous professional antigen presenting cells (APC) such as macrophages, dendritic cells, or activated B or T lymphocytes. See Lanzavecchia, supra, p. 937. Professional APCs express a ligand, B7, that binds to CD28 or CTLA4 on T cells to deliver an antigen- nonspecific costimulatory signal known as Signal 2 which prevents T cell anergy or inactivation. Thus, the vaccine may also comprise interleukin-2 or another costimulatory signal to counteract anergy induction. (Lanzavecchia, supra, p. 938.) Another formulation of a mammaglobin-specific vaccine comprises a recombinant vector containing a nucleotide sequence encoding for expression a mammaglobin antigen. The use of infectious agents to stimulate cytotoxic T lymphocytes is known in the art. (Raychaudhuri, supra.) Chimeric vectors have been described using vaccinia, polio, adeno- and retro-viruses, as well as bacteria such as Listeria and BCG. For example, a canarypox virus vector, ALVAC, has been shown to elicit strong cellular immune responses against encoded heterologous gene products (Taylor et al, Virology 187:321-328 (1991)). In addition, a recombinant ALVAC expressing the MZ2-E human melanoma rejection antigen encoded by the MAGE-1 gene is able to stimulate in vitro MAGE-1 CTL activities in a TIL population derived from a breast tumor expressing MAGE-1 mRNA (Toso et al, supra). In another approach described in U.S. Patent No. 5593972 to Weiner et al, a recombinant expression vector encoding an antigen of an immunogenic protein to be targeted is directly administered to an individual either in vivo, to muscle cells, or to the WO 00/18783 PCTIS99/22616 cells of an individual ex vivo along with an agent that facilitates uptake of the DNA into the cells.
Those skilled in the art may readily determine how to formulate a vaccine suitable for achieving the desired immune response. For example, for inducing in vivo production of anti-mammaglobin antibodies, a mammaglobin-specific vaccine comprises at least one mammaglobin B cell antigen comprising a B cell epitope and a TH cell epitope. The TH cell epitope is preferably matched with the appropriate MHC class II haplotype of the intended vaccine recipient. Alternatively, a TH cell epitope could be used that is known to be recognized universally by humans regardless of HLA type such as the "universal" T cell epitope from tetanus toxoid (Panina- Bordignon et al. Eur. J. Immunol. 19:2237 (1989). Preferably, the vaccine comprises a plurality of mammaglobin B cell antigens with TH epitopes recognized by MHC Class II molecules of different HLA types.
Another embodiment of a mammaglobin-specific vaccine induces a cellmediated response and comprises at least one mammaglobin Tc antigen capable of activating mammaglobin-specific Tc cells. Preferably, the vaccine comprises several Tc cell antigens.
A mammaglobin-specific vaccine may also be formulated to induce both antibody and cell-mediated responses. This embodiment comprises both mammaglobin B cell and Tc cell antigens.
A patient with a mammaglobin-expressing tumor may be treated by administering to the patient an immunostimulatory amount of a mammaglobinspecific vaccine according to the present invention. Administration of the vaccine may be by any known or standard technique. These include, but are not limited to intravenous, intraperitoneal, intramuscular, subcutaneous, or intramammary injection.
Preferred embodiments of the invention are described in the following examples. Other embodiments within the scope of the claims herein will be apparent to one skilled in the art from consideration of the specification or practice of the invention as disclosed herein. It is intended that the specification, together with the examples, be considered exemplary only, with the scope and spirit of the invention being indicated by the claims which follow the examples.
WO 00/18783 PCT/US99/22616 26 In the examples below, cell lines were obtained from American Type Culture Collection and grown in Dulbecco's minimal essential medium supplemented with fetal calf serum. Tissue biopsy specimens were obtained from the Human Cooperative Tissue Network (LiVolsi et al, Cancer 71:1391-1394, 1993).
Example 1 This example illustrates the isolation of mammaglobin cDNA.
Total cellular RNA from the cell line MDA-MB415 was isolated using the standard guanidinium isothiocyanate method. (Belyavsky et al, supra). This RNA was used in the RACE PCR procedure employing the Amplifinder kit (Clonetech) and following the manufacturer's protocol.
The synthesis of first strand cDNA was performed in a standard reaction containing 1 pg RNA, 10 jM specific mammaglobin primer D2R (5'-ATA AGA AAG AGA AGG TGT GG-3')(SEQ ID NO:4), 4jl of 5X RT buffer (250 mM TrisCI pH8.3, 375mM Kcl, 15mM MgCl 2 2 [l of 100mM DTT, 1 pl of 10 mM dNTPs and 200 units of SuperscriptTM II reverse transcriptase (Gibco/BRL) in a reaction volume jl. The reaction proceeded for 1 hour at 45 0 C and was terminated by incubating at for 5 minutes. RNA was hydrolyzed with 400 jpM NaOH at 65 0 C for minutes and neutralized with 400 p.M acetic acid.
The reaction mixture was then added to 3 volumes of 6M Nal and 10 al of treated glass beads. Beads were washed three times with 80% EtOH and nucleic acid was eluted from the beads in 45 pl of water. Nucleic acid was then precipitated and resuspended in 10 pl of water. The purified first strand cDNA was ligated to the manufacturer's provided anchor oligonucleotide (SEQ ID NO:9, 5'-CAC GAA TTC ACT ATC GAT TCT GGA ACC TTC AGA using T4 RNA ligase at 270 for hours. One tenth of a ligation reaction was used for PCR amplification in a 50 pl reaction containing 1 jtM manufacturer's anchor primer (SEQ ID NO:10, GTT CGG CCC ACC TCT GAA GGT TCC AGA ATC GAT 1 jiM mammaglobin specific primer D2Rb (SEQ ID NO:11, 5'-AAT CCG TAG TTG GTT TCT CAC 200 iM dNTPs, 5 units of Vent T M DNA polymerase, and 1X polymerase buffer (10mM Kcl, 20 mM TrisCl, 10 mM (NH4) 2 S0 4 2 mM MgSO 4 WO 00/18783 PCT[US99/22616 27 0.1% Triton X-100). The reaction was incubated at 940 for 2 minutes and then 940 for 45 seconds, 500 for 1 minute, and 720 for 90 seconds for a total of 40 times.
The two downstream mammaglobin-specific nested oligonucleotides were D2R (SEQ ID NO:4) and D2Rb (SEQ ID NO:11). An upstream mammaglobinspecific control oligonucleotide was also used as per the manufacturer's recommendations, D2F (5'-CTT TCT GCA AGA CCT TTG GC-3') (SEQ ID NO:12).
All PCR amplifications were performed with Vent DNA polymerase (New England Biolabs). The amplified RACE product was digested with EcoRI and ligated into the EcoRI and Smal sites of the plasmid vector pGEM7Z (Promega, Madison, WI).
All sequencing was performed using the Taq DNA polymerase thermal cycle sequencing kit as per the manufacture's protocol (Promega). Briefly the procedure used is as follows.
Ten pmol of sequence specific oligonucleotide was end labeled with 10 pmol of 32 P-y ATP (3,000 Ci/mmol and 10 mCi/ml) using T4 polynucleotide kinase in a pl reaction for 30 minutes at 37 0 C. A polymerization reaction containing 100 ng of plasmid template, 1.5 pmol of labeled sequencing primer, and 5 units of sequencing grade Taq polymerase was created in 17 pl of the manufacturer's provided sequencing buffer. This reaction was aliquoted to a set of four reaction tubes containing manufacturer's provided mix of deoxynucleotides and either dideoxy-A, C, G, or T.
The set of four tubes were incubated at 95 0 C for 2 minutes and then, 94°C for seconds, 45 0 C for 30 seconds, and 72 0 C for 1 minute for 30 times. After reactions were completed, 3 pl1 of 80% formamide/bromphenol blue dye was added to each tube. Samples were heated to 70 0 C for 2 minutes and loaded on a 6% M urea sequencing gel and run for 2-4 hours and 60 W constant power. The gel was dried and then exposed to Kodak XAR5 Xray film for 2 to 24 hours.
The sequence thus obtained was a 403 bp fragment (SEQ ID NO:5) as shown in FIG 2, solid bar. In earlier work the DEST002 Tag sequence was isolated (Watson and Fleming, supra). This sequence was a 206 bp fragment (SEQ ID NO:6) as shown in FIG 2, open bar. Combining the information from these two sequences allowed the full-length 503 bp cDNA of mammaglobin to be deduced. (FIG 2).
WO 00/18783 PCTIUS99/22616 28 Example 2 This example demonstrates that mammaglobin expression is restricted to mammary gland tumor cells and, to a lesser extent, normal mammary gland cells.
Total cellular RNA samples were isolated using the standard guanidinium isothiocyanate method and treated with RNase-free DNase (Promega). For RT/PCR analysis, 1 jpg of indicated total RNA was reverse transcribed with oligo dT 2 1
(SEQ
ID NO:13) and Superscript II reverse transcriptase (Gibco/BRL) according to the manufacture's protocol.
Two hundred ng of oligo dT 21 (SEQ ID NO:13) and 1 [lg of total RNA were incubated at 65 0 C for 5 minutes in a 10 pl volume. Sample was chilled on ice and added to it were 4jl of 5X RT buffer (250 mM TrisCI pH8.3, 375 mM Kcl, 15 mM MgCl 2 2 pl of 100mM DTT, 1 pl of 10mM dNTPs and 200 units of Superscript T M
II
reverse transcriptase (Gibco/BRL). The reaction proceeded for 1 hour at 45 0 C and was terminated by incubating at 95°C for 5 minutes.
One tenth of each RT reaction was subject to PCR analysis using the mammaglobin specific primers D2R (5'-ATA AGA AAG AGA AGG TGT GG-3') (SEQ ID NO:4) and d2102 (5'-CAG CGG CTT CCT TGA TCC TTG-3') (SEQ ID NO:3) and standard reaction conditions for 40 cycles at 940 x 30 sec./55 0 x 1 min./72° x 1 min.
For Northern analysis, 20 pg of total RNA was analyzed as previously described (Watson and Fleming, supra) using the full length mammaglobin cDNA probe. Integrity and equal loading of each RNA sample was assessed by ethidium bromide staining.
As shown in FIG 4A, the 500 bp mammaglobin message is easily detected in tumor specimen 2410 (the tissue from which this original DEST was isolated) and to a much lesser extent in normal human breast tissue but not in the immortalized breast epithelial cell line B5-589, or in human lung, placenta, uterus and ovary (FIG 4A).
Following amplification using RT/PCR analysis, mammaglobin expression was still not detected in 15 tissues surveyed (FIG 4B). Detection of glyceraldehyde 3phosphate dehydrogenase (GAPDH) message (FIG 4B) and EGF receptor message (data not shown) in these reactions demonstrated that absence of expression was not WO 00/18783 PCT[US99/22616 29 due to degraded RNA or other trivial explanations. Thus the expression of mammaglobin mRNA is relatively specific for mammary tissue.
Example 2A This example confirms the breast specificity of mammaglobin expression in normal tissues.
The mammaglobin cDNA probe used in Example 2 was hybridized to a commercially prepared dot-blot of normalized, poly-A enriched RNAs derived from pooled populations of normal human tissues (Master Blot
TM
Clonetech, Palo Alto, CA). The dot-blot contained RNA from the following human tissues: whole brain, amygdala, caudate nucleus, cerebelum, cerebral cortex, frontal lobe, hippocamus, medulla oblongata, occipital lobe, putamen, substantia nigra, temporal lobe, thalamus, nucleus accumbeus, spinal cord, heart, aorta, skeletal muscle, colon, bladder, uterus, prostate, stomach, testis, ovary, pancreas, pituitary gland, adrenal gland, thyroid gland, salivary gland, mammary gland, kidney, liver, small intestine, spleen, thymus, peripheral leukocyte, lymph node, bone marrow, appendix, lung, trachea, placenta, fetal brain, fetal heart, fetal kidney, fetal liver, fetal spleen, fetal thymus, and fetal lung.
The mammaglobin cDNA probe was radiolabled with 3 2 P-o-dCTP mCi/ml; >3000 Ci/mmol) and the Rediprime labeling kit (Amersham, Arlington Heights, IL.) following the supplier's protocol. The dot blot was hybridized with lx106 CPM ml of the mammaglobin cDNA probe at 60 0 C for 16 hours using Rapid- Hyb hybridization buffer (Amersham, Arlington Heights, Filters were then washed twice at room temperature for 15 min. in 2X SSC 0.1% SDS, and washed twice again at 60 0 C for one hour in 0.2X SSC 0.1% SDS. Washed filters were exposed to XAR5 film (Eastman-Kodak, Rochester, NY.) with phosphor enhancing screens for 72 hours.
Mammaglobin mRNA was only detected in RNA from the mammary gland (data not shown). The lack of detectable mammaglobin mRNA in normal salivary gland and prostate indicates that mammaglobin expression is not associated with the apocrine phenotype as opposed to the apocrine cell specificity of GCDP15, which has been used as a breast-specific marker. Wick et al., Hum Pathol 20:281-287, 1989; Raab et al., Am J Clin Pathol 100:27-35, 1993. These results suggest potential WO 00/18783 PCT/US99/22616 advantages for using mammaglobin gene expression as a very specific marker for breast cancer.
Example 3 This example demonstrates that the mammaglobin cDNA encodes a translatable nucleotide sequence which results in a protein product of appropriately predicted molecular mass. In vitro translations were performed using the TNTTM rabbit reticulocyte translation kit with T7 RNA polymerase (Promega) and 35
S-
Methionine (>1000 Ci/mmol; 10 mCi/ml, Amersham) according to the manufacturer's protocol.
To 25 tl of TNTT rabbit reticulocyte lystae was added 2 pl of manufacturer's prepared reaction buffer, T7 RNA polymerase, 20pM amino acid mixture minus methionine, 40pjCi 35 S-methionine (1,000 Ci/mmol and 10 mCi/ml), 40 units ribonuclease inhibitor, 1 pg of mammaglobin/pGEM7 plasmid, and sufficient DEPC treated water to create a final reaction volume of 50 il. This reaction was incubated at 30 0 C for 60 minutes. 5pl of this reaction was removed into 20pl of SDS gel buffer, boiled for 2 minutes, and loaded on a 17.5% SDS-polyacrylamide gel.
Rabbit reticulocyte lysate programmed with mammaglobin cDNA produced a 6kD protein while that programmed with no cDNA did not produce any protein product.
Example 4 This example illustrates the prevalence of overexpression of mammaglobin in primary breast carcinoma.
To determine the frequency of mammaglobin overexpression in breast carcinomas, we examined a panel of fifteen, stage I primary breast carcinomas of differing histological types using Northern blot hybridization with the mammaglobin cDNA probe. Patient-matched normal breast tissues samples were also compared in tissues from two patients (FIG The 500 bp mammaglobin mRNA was detected in normal breast tissue and tumor 2410 and in three other tumors, two of which when tested demonstrated little or no expression in patient-matched normal tissue (BO 15 v.
WO 00/18783 PCT/US99/2616 31 B016; B022 v. B023) (FIG In all, 4 of 15 of tumors examined overexpressed mammaglobin mRNA.
These data indicate that overexpression of mammaglobin is not unique to a single tumor specimen and is, in fact, relatively frequent among primary breast tumors. Furthermore, the fact that all tumors examined were stage I suggests that this dysregulation occurs relatively early in the progression of breast neoplasia.
Example The following example illustrates the detection of the mammaglobin protein using an anti-mammaglobin polyclonal antibody.
The anti-mammaglobin polyclonal antibody was prepared by coupling a peptide corresponding to the 16 C-terminal amino acids predicted from mammaglobin cDNA (Glu-Val-Phe-Met-Gln-Leu-Ile-Tyr-Asp-Ser-Ser-Leu-Cys-Asp-Leu-Phe,
SEQ
ID NO: 14) to Keyhole Lymphet Hemocyanin and injecting into rabbits with Freund's adjuvant. The inoculated rabbits were boosted at three week intervals and on week 12, the rabbits were bled and the sera was assayed for its ability to detect mammaglobin in serum-free conditioned medium from cultures of the breast tumor cell lines MDA-MB-415 and MCF-7. MDA-MB-415 had been identified earlier as a cell line that overexpresses the mammaglobin message and MCF-7 had been identified as a cell line that produces no detectable mammaglobin mRNA.
The conditioned media was harvested from a 24 hr. culture and resolved on a 12% SDS acrylamide gel under reducing conditions the sample was boiled in buffer containing dithiothreitol (DTT) and 2-mercaptoethanol (BME) to reduce disulfide bonds), blotted onto a Nytran filter, and analyzed by standard Western blot protocols using the above described antibody to the C-terminal peptide as the primary antibody in this assay. After primary antibody binding, the blot was washed and secondary antibody (goat anti-rabbit) was added. Mammaglobin-antibody complexes were visualized by enzyme-linked chemiluminescence (ECL Western Blotting Detecting Reagent, Amersham, Arlington Heights, IL).
The anti-mammaglobin polyclonal antibody detected a band with an apparent molecular weight of approximately 21 kD in the conditioned media of the MDA-MB- 415 cell culture (data not shown). No bands were detected in the conditioned medium WO 00/18783 PCTIUS99/22616 32 of the MCF-7 cell culture (data not shown). Thus, consistent with the mRNA data, MDA-MB-415 cells secrete mammaglobin protein but MCF-7 cells do not. The apparent molecular weight of the mammaglobin secreted into the MDA-MB-415 culture media is greater than the 10.5 kDa molecular weight calculated from the predicted amino acid sequence of SEQ ID NO:2. Since almost all secreted proteins are glycosylated, the cytosol of MDA-MB-415 cells was analyzed with the antimammaglobin polyclonal antibody to see if any precursor forms of secreted mammaglobin could be detected.
MDA-MG-415 cells were grown for 24 hours in serum-free media, the culture media was collected, spun, and the resulting supernatant was collected. The attached cells were washed with phosphate buffered saline (PBS) and lysed with 1X Laemmli sample buffer SDS, 10% glycerol, 100 mM DTT, 60 mM Tris, pH 6.8, 0.001% Bromophenol Blue). The lysis mixture was boiled for 5 minutes and then spun at 10,000 g for 5 minutes to pellet the cell debris. The cell lysate was transferred to a new tube and used for Western blot analysis as described below.
The culture supernatant and cell lysate were run on a 12% SDS acrylamide gel under reducing conditions samples boiled in buffer containing DTT and BME) and blotted onto a PVDF membrane using standard techniques. The blot was probed with the polyclonal antibody to the C-terminal peptide in the presence and absence of the competing peptide used to generate the antibody.
Visualization of mammaglobin-antibody complexes were as discussed above.
As seen in Figure 7, in the absence of competing peptide the conditioned media has the 21 kD band representative of the secreted mammaglobin protein. The cell lysate showed a prominent band at approximately 14 kD, and several higher molecular weight bands, including one at approximately 21 kD. When the Western blot is performed in the presence of the competing peptide the secreted form and intracellular forms of mammaglobin are not visualized, indicating that these proteins contain the peptide to which the antibody was synthesized.
The 14 kD band detected only in the cell lysate likely represents a precursor, or unprocessed, form of mammaglobin. Since the predicted amino acid sequence for mammaglobin has the consensus N-glycosylation site, Asn-X-Thr, located at residues WO 00/18783 PCTIUS99/22616 33 53-55 and at residues 68-70 of SEQ ID NO:2, the observed, secreted 21 kD form likely represents some glycosylated form of the protein.
This hypothesis was tested by culturing MDA-MB-415 cells in the presence and absence of tunicamycin, a drug that blocks N-linked glycosylation of eukaryotic proteins. Tunicamycin was added to one of two identical cultures at 1 ug/ml and both cultures were incubated overnight for more hours. The culture media and cell lysate from the treated and control cultures were prepared and analyzed by Western blot analysis as described above.
As shown in FIG 8, media from cultures treated with tunicamycin lack detectable levels of secreted mammaglobin, suggesting that secreted mammaglobin is glycosylated. Surprisingly, the cell cytosol form of mammaglobin (14 kD) was also not detectable in lysates of MDA-MB-415 cells treated with tunicamycin (far right lane). We hypothesize that blocking early glycosylation events with tunicamycin leads to instability and degradation of precursor forms of mammaglobin, thus explaining the lack of detectable 14 kD protein in the cytosol of tunicamycin-treated cells.
The polyclonal antibody to the C-terminal peptide of mammaglobin has also detected the 14 kDa precursor form of mammaglobin in cell lysates from primary human breast tumor specimens. As seen in FIG 9, the precursor form of mammaglobin is present in tumor specimen B023, but is undetectable in a normal breast tissue sample from the same patient (B022). Interestingly, some tumor samples that express the mammaglobin transcript 087R, 014, 75A and 2410) do not contain detectable levels of mammaglobin protein as assayed by Western blot analysis. One hypothesis consistent with these data is that mammaglobin expression is differentially regulated at the levels of transcription and translation and that this differential regulation is determined the developmental stage of the tumor.
The anti-mammaglobin polyclonal antibody has also been used to look for secreted mammaglobin in breast secretions from proliferating mammary gland.
Colostrum or mature milk fluid (500 ul samples) was collected by manual expression from a pregnant woman during the first and third trimester, at birth, and at day 3, 14, and 21 post-partum. The samples were diluted with an equal volume of 2X laemmli sample buffer SDS, 20% glycerol, 200 mM DTT, 120 mM Tris, pH 6.8, 0.002% WO 00/18783 PCT/US99/22616 34 Bromophenol Blue). The diluted samples were boiled for 5 min. and then spun at 10,000 g for 5 min. at 4 0 C to pellet cell debris. The denatured samples were transferred to a new tube and stored at -20 0 C prior to Western blot analysis as described above.
As shown in FIG. 10, the antibody detected the 21 kD secreted mammaglobin in breast secretions sampled during pregnancy, a period of high proliferation of breast epithelial cells. However, at the onset of lactation, a stage of breast epithelial differentiation, mammaglobin levels decreased significantly by 3 days post partum and was no longer observed at 14 days post-partum. These results indicate that secreted mammaglobin is associated with proliferating breast epithelial cells, an observation consistent with the detection of secreted mammaglobin in human breast cancer.
Reactivity with the antibody to the mammaglobin peptide has also been shown for breast tumor cells by immunohistochemical staining of paraffin-fixed sections of a breast cancer patient specimen (FIG. 11). The immunohistochemical staining was performed using the antibody to the mammaglobin peptide as the primary antibody and then detecting the mammaglobin-antibody complex using goat anti-rabbit antibody tagged with horseradish peroxidase and 3, 3' diamino benzene tetrahydrochloride (DAB) as substrate. Cells expressing the mammaglobin protein showed a brown staining.
From the results, it is believed that the mammaglobin protein is synthesized as a precursor protein and post-translational modifications such as N-linked glycosylation increase its apparent molecular weight prior to secretion; that the stability of precursor forms of mammoglobin is dependent on N-linked glycoslyation and that mammaglobin protein is secreted by proliferating breast tumor cells.
Example 6 This example illustrates detection of mammaglobin protein in primary breast tumors by immunohistochemical analysis using the anti-mammaglobin rabbit polyclonal antibody described in Example One hundred archived breast tumor specimens were chosen at random from the Vanderbilt University Department of Pathology and the Washington University WO 00/18783 PCT/US99/22616 Cancer Center Tumor Repository. Formalin-fixed, paraffin-embedded tissues were cut at 5 rLm, mounted on charged slides, and dried.
For immunohistochemical analysis, slides were deparaffinized and rehydrated in graded solutions of ethanol and distilled water. Tissue sections were preincubated with normal goat serum (Vector Laboratories, Burlingame, CA.) at a 1:100 dilution in 3% bovine serum albumin (BSA) phosphate buffered saline (PBS) and then with the anti-mammaglobin rabbit polyclonal antibody at a 1:1000 dilution for 1 hour at room temperature. After several rinses in PBS, sections were incubated in a solution of normal goat serum (1:1000), 3% BSA, and 6 pg/ml of biotinylated goat anti-rabbit IgG (Vector Laboratories, Burlingame, CA.) in PBS for 1 hour. The secondary antibody solution was rinsed four times in PBS and tissues were then incubated with a 1:1000 dilution of streptavidin peroxidase (Boehringer Mannheim, Indianapolis, IN.) also in a solution of 3% BSA PBS. After a 30 minute incubation, slides were again rinsed four times in PBS and exposed to chromagen solution containing 1 mg/ml 3,3'-diaminobenzidine tetrahydrochloride (Dako, Carpinteria, CA) and 0.02% hydrogen peroxide for 3 minutes. Slides were rinsed briefly in deionized water, counterstained with Harris' hemotoxylin, and mounted under coverslips.
For negative controls, tissue sections were processed identically except a 1:500 dilution of pre-immune rabbit serum was substituted for the anti-mammaglobin antiserum. Alternatively, for peptide competition experiments, mammaglobin antiserum was first incubated with the 16 residue mammaglobin peptide at a concentration of 100 Vg/ml in 3% BSA/PBS for 1 hour at room temperature and then applied to tissue sections.
Immunopositivity was scored as 0: no staining, 1: weak and sporadic staining in less than 50% of tumor cells, 2: weak staining in greater than 50% of tumor cells, 3: strong, diffuse cytoplasmic staining in less than 50% of tumor cells, 4: strong, diffuse cytoplasmic staining in greater than 50% of tumor cells. Only sections scoring 3 or 4 were considered mammaglobin "positive". The scoring results are shown in Table I below and representative staining patterns for three tumor types are shown in Figure 12.
1 Table 1. Mammaglobin immunoreactive staining in human breast cancer Tumar Tvn
I
Staininu Scorp 2 4 3 2 1 0 Total Lobular Well Differentiated Moderately Differentiated Poorly Differentiated
DCIS
Total 11(78%) 28 (67%) 24 (63%) 1(33%) 64 1 (33%) 0 5 (12%) 9 (24%) 2 (67%) 1 (33%) 1 3 2 0 0 2 0 0 2 1 (33%) 2 (14%) 4(10%) 3 Except for lobular and ductal carcinoma in situ (DCIS), all speciments are invasive ductal cancers.
2 The degree of immunopositive staining of breast tumor tissue sections with anti-mammaglobin antibodiy was rated as 0: No staining, 1: Weak staining in <50% of tumor cells, 2: Weak staining in >50% of tumor cells, 3: Strong, cytoplasmic staining in <50% of tumor cells, 4: Strong, cytoplasmic staining in >50% of tumor cells. For purposes of discussion, mammaglobin 'positive' tumors are those that scored 3 or 4.
WO 00/18783 PCT[US99/22616 37 Overall, 80% of ductal carcinomas examined demonstrated strong global or focal cell staining for mammaglobin protein. Interestingly, staining was equally frequent among well differentiated moderately differentiated and poorly differentiated tumors (Table 1, Figure 12). Strong staining was also seen in 3/3 cases of pure ductal carcinoma in situ (DCIS) (FIG. 12A). The cellular staining pattern of mammaglobin was predominantly diffuse and cytoplasmic, although some cells also demonstrated localized staining adjacent to the nucleus. In normal breast tissue, mammaglobin staining was observed only in rare epithelial cells within small ducts and lobules.
However, as has been observed with other secretory proteins, increased expression of mammaglobin coincided with features of apocrine metaplasia. In benign breast tissue with metaplastic apocrine epithelium, mammaglobin immunoreactivity was present both within the epithelium and in the apocrine cyst fluid. The specificity of these patterns of positive staining were documented by the lack of signal from identical specimens incubated with either pre-immune rabbit serum (FIGS. 12B, 12D, 12F) or anti-mammaglobin antiserum preincubated with competing C-terminal peptide (data not shown).
However, mammaglobin expression was not detected in other apocrine tissues such as the normal prostate and salivary gland. Furthermore, breast tumor cells with both apocrine and non-apocrine features express mammaglobin with roughly equal frequency and intensity. There is also apparently no correlation between mammaglobin expression and tumor grade. Therefore, it is believed that mammaglobin expression is a marker of a unique breast tumor phenotype and may be useful in conjunction with other established markers to further define breast tumors at the molecular level.
The results described in Examples 5 and 6 indicate that detection of a mammaglobin protein will be applicable in cancer diagnostics using the mammaglobin protein as a breast tumor marker, in assessing breast tumor relapse, in monitoring autologous bone marrow/stem cell transplants for contaminating tumor cells, and in targeting breast tumor cells for therapeutic intervention via antibodymediated complexes. A purified and isolated mammaglobin polypeptide is useful for WO 00/18783 PCTIUS99/22616 38 generating antibodies against breast tumors and in the development of other tumorspecific immunotherapy regimens.
Example 7 This Example illustrates the detection of mammaglobin mRNA in lymph nodes.
Mammaglobin's expression in a large percentage of primary breast tumors and its absence in lymphoid tissues suggested that it would be a sensitive and specific marker for detecting metastatic breast tumor cells within lymph nodes. To test this idea, mammaglobin mRNA expression was examined in lymph nodes containing either histologically documented breast metastases or other non-mammary metastatic tumors. Expression of mammaglobin was also compared to that of keratin 19, an epithelial cell-specific marker, to normalize marmnaglobin signals to the total number of malignant epithelial cells present in each lymph node sample.
Anonymized lymph node specimens containing metastatic lesions were obtained from the Cooperative Human Tissue Network (LiVolsi et al., Cancer 71:1891-1894, 1993) and the Washington University Cancer Center Tumor Repository. Tissue specimens were pulverized and homogenized in Trizol reagent (Life Technologies, Rockville, MD) at a concentration of 100 mg of tissue per ml of reagent. RNA isolation was performed exactly as recommended in the manufacturer's protocol and the resulting RNA was resuspended at a concentration of 2 Lig/pl in RNase-free water. Twenty pig of each RNA was subjected to formaldehyde agarose gel electrophoresis and transferred to Nytran Plus membranes (Schleicher Schuell, Keene, NH) using 1 OX SSC buffer and standard methodology.
To generate a mammaglobin hybridization probe, the mammaglobin cDNA used in Example 2 was radiolabled with 32 P-o-dCTP (10 mCi/ml; >3000 Ci/mmol) and the Rediprime labeling kit (Amersham, Arlington Heights, IL) following the supplier's protocol.
A keratin 19 hybridization probe was constructed as follows. Forward (5 '-CGCGGATCCAGGATTGTCCTGCAGAT-3') (SEQ ID NO:18) and reverse CCCTCTACCCAGA-3') (SEQ ID NO:19) keratin 19 specific oligonucleotide sequences were used in a standard PCR amplification WO 00/18783 PCT/US99/22616 39 reaction of normal human breast cDNA to generate a k19 cDNA fragment encompassing the coding region from nucleotide 477 to nucleotide 1298 (Stasiak, P.C. and Lane, Nucleic Acids Res 15:10058, 1987.). This fragment was digested to generate EcoRI and BamHI ends, cloned into the corresponding sites of the pGEM3Z vector (Promega, Madison, WI) and sequenced to confirm identity. The cloned, 821 bp kl9 cDNA fragment was radiolabled as described above.
The Northern blot filters were first hybridized with lxl06 CPM/ml of the mammaglobin hybridization probe at 60°C for 16 hours using Rapid-Hyb hybridization buffer (Amersham, Arlington Heights, IL). Filters were then washed twice at room temperature for 15.min. in 2X SSC/0. 1% SDS, and washed twice again at 60 0 C for one hour in 0.2X SSC/0.1% SDS. Washed filters were exposed to film (Eastman-Kodak, Rochester, NY) with phosphor enhancing screens for 72 hours.
The filters were allowed to decay for several half-lives and then rehybridized with lxl06 CPM/ml of the keratin 19 hybridization probe without pretreatment of the filters. Equal counts and specific activities of mammaglobin and keratin 19 cDNA probes were used and each hybridization was exposed to film under equivalent conditions.
The results of this survey are shown in Figure 13. Among 21 cases of lymph nodes containing histologically documented metastatic breast cancer (lanes 1-20, 27), mammaglobin expression could be detected in 9 of the cases (lanes 1, 2, 7, 9, 11, 12, 17, 18, and 27). However, in 6 of the 21 cases, neither mammaglobin nor keratin 19 mRNA could be detected (lanes 3, 5, 6, 10 13, 14, 16, 19 and suggesting that the lymph node samples from these cases may have contained too few tumor cells to be assayed by this method. When these six cases were excluded, (9/15) of cases contained detectable mammaglobin mRNA. In at least one case, mammaglobin expression was detected in the absence of keratin 19 expression (lane 27), suggesting that mammaglobin may be a more sensitive marker in a subset of tumors. Furthermore, keratin 19 was ubiquitously expressed in many cases of nonmammary metastases, lymph nodes with laryngeal and billary tumor involvement (lanes 21-26), while mammaglobin expression was detected in only one case of a nonmammary metastatic lesion (lane 22). This case was an inguinal lymph node containing poorly-differentiated adenocarcinoma of unknown origin. Since a WO 00/18783 PCT[US99/22616 previous history of endometrial cancer was documented, this lesion was presumed to be a metastatic recurrence of the disease. We have recently detected mammaglobin expression in several primary endometrial cancers (data not shown), thus confirming the idea that mammaglobin, while not expressed in normal endometrial tissue, is expressed in a subset of endometrial as well as breast cancers. In all cases of lymph nodes without metastatic disease (lanes 29-33), both keratin 19 and mammaglobin expression were undetectable. As expected mammaglobin mRNA was detected in RNA isolated from normal breast tissue (lane 34).
Example 8 This example illustrates detection of mammaglobin mRNA in peripheral blood stem cell (PBSC) collections as a marker for circulating breast tumor cells.
Aliquots of -x 106 peripheral leukocytes were obtained from leukopheresis products of 15 patients undergoing high dose chemotherapy and autologous stem cell transplant for metastatic breast cancer. For positive controls, 10' mammaglobinexpressing MDA-MB175 human breast tumor cells (Watson et al., Cancer Res 56:860-865, 1996.) were mixed with 106 human OM431 melanoma cells to yield a 1:105 breast cancer cell dilution. A pure population of OM431 cells was used as a negative control. Frozen cell aliquots were immediately lysed in 1 ml of Trizol reagent (Life Technologies, Rockville, MD) and total RNA was prepared as per the supplier's protocol. RNA integrity and concentration was assessed by agarose gel electrophoresis.
Approximately one microgram of total RNA was converted to first-strand cDNA using a T, 1-17 primer and the Superscript II preamplification system (Life Technologies, Rockville, MD) as per the supplier's protocol. After treatment with and inactivation of RNase H, samples were diluted two-fold with nuclease-free water and stored at -20 0 C. To assess the integrity of synthesized cDNA, 10% of the cDNA was subjected to a 50 pl PCR reaction containing a final concentration of lX Taq DNA polymerase buffer, 1.5 mM MgCl 2 200 (tM dNTPs, 0.6 jtM Glyceraldehyde-3- Phosphate Dehydrogenase (GAPDH) forward amplification primer (5'-CCACCCATGGCAAATTCCATGGCA-3') (SEQ ID NO:20), 0.6 utm GAPDH reverse amplification primer (5'-TCTAGACGGCAGGTCAGGTCCACC-3')
(SEQ
WO 00/18783 PCTIUS99/22616 41 ID NO:21), and 2.5 units Taq DNA polymerase (Life Technologies, Rockville, MD).
Reactions were heated to 94°C for 1 minute and then subjected to 30 cycles of 94°C for 30 seconds, 58C for 60 seconds, and 72 0 C for 45 seconds. PCR products were analyzed on a 2% agarose gel and a single, uniformly intense fragment of 599 nt.
indicated that each cDNA synthesis reaction had been successful. An additional of the cDNA reaction was then subjected to a second 50 gl PCR reaction containing a final concentration of IX Taq DNA polymerase buffer, 1.5 mM MgCl 2 200 .M dNTPs, 0.6 4M mammaglobin forward amplification primer (5'-AGCACTGCTACGCAGGCTCT-3') (SEQ ID NO: 16), 0.6 pm mammaglobin reverse amplification primer (5 '-ATAAGAAAGAGAAGGTGTGG-3') (SEQ ID NO:4), and 2.5 units Taq DNA polymerase (Life Technologies, Rockville, MD).
Reactions were heated to 94 0 C for 1 minute and then subjected to 45 cycles of 94°C for 30 seconds, 58 0 C for 60 seconds, and 72 0 C for 30 seconds. Amplification products were delivered to an alternate laboratory site, electrophoresed on a 2% agarose gel, and subjected to Southern blot analysis using 0.2 Pm Nytran Plus membrane and the supplier's protocol for the neutral transfer method (Schleicher Schuell, Keene, The resulting filter was hybridized with 1x10 6 CPM ml of mammaglobin cDNA probe and washed as described above.
The results of this assay are shown in Figure 14. Of fifteen breast cancer cases nine patients yielded detectable mammaglobin mRNA from their PBSCs, suggesting that the collected products contained contaminating breast tumor cells. In the remaining six cases, because the primary tumors were not examined for mammaglobin expression, it was not known whether the lack of signal for the PBSCs represented a lack of mammaglobin-expressing tumor cells, a true absence of tumor cells, or assay insensitivity. In no cases of collections from healthy donors (NL) was mammaglobin mRNA detected. Based on the robust hybridization signal obtained from duplicated positive controls containing 1:105 breast tumor cells, the limit of detection for the current assay format is probably well below 1:106 cells. The frequency of detection and high specificity of this assay suggest that it may be a useful tool for studying the prognostic significance of occult circulating tumor cells in larger, prospective studies. For example, mammaglobin expression may be useful to evaluate tumor contamination of peripheral stem cell products after cytokine priming 42 (Passos-Coelho et al., J. Clin. Oncol. 14:2569-2575, 1996) or tumor cell purging protocols (Passos-Coelho et al., Cancer Res. 54:2366-2371, 1994).
In view of the above, it will be seen that the several advantages of the invention are achieved and other advantageous results attained.
As various changes could be made in the above methods and compositions without departing from the scope of the invention, it is intended that all matter contained in the above description and shown in the accompanying drawings shall be interpreted as illustrative and not in a limiting sense.
All references cited in this specification, including patents and patent applications, are hereby incorporated by reference. The discussion of references herein is intended merely to summarize the assertions made by their authors and no admission is made that any reference constitutes prior art. Applicants reserve the right to challenge the accuracy and pertinency of the cited references.
With reference to the use of the word(s) "comprise" or "comprises" or "comprising" in the foregoing description and/or in the following claims, unless the context requires otherwise, those words are used on the basis and clear understanding that they are to be interpreted inclusively, rather than exclusively, and that each of those words is to be so interpreted in construing the foregoing description and/or the following claims.
*o o o *oo o *ooo EDITORIAL NOTE APPLICATION NUMBER 62758/99 The following Sequence Listing pages 1 to 5 are part of the description. The claims pages follow on pages 43 to 44.
WO 00/18783 WO 0018783PCTIUS99/2261 6 SEQUENCE LISTING <110> WATSON, MARK A FLEMING, TIMOTHY P <120> Mammaglobin, A Secreted Protein Mammary-Specific Breast Cancer <130> 6029-5134 <140> <141> <150> 08/933,149 <151> 1997-09-18 <150> PCT/US96108235 <151> 1996-05-31 <150> 08/455,896 <151> 1995-05-31 <160> 21 <170> Patentln Ver. <210> 1 <211> 503 <212> DNA <213> Homo sapiens <400> 1 gacagcggct atgaagttgc ggctgcccct gaatacaaag gaattgaagg atgcaattaa gctcacagaa ctctttctta tttattttaa tccttgatcc tgatggtcct tattggagaa aacttcttca aatgttttct tatatgacag ctgcagggta tgtcttttta taaattgatg ttgccacccg catgctggcg tgtgatttcc agagttcata taaccaaacg cagtctttgt tggtgagaaa ctacaaacta gca cgactgaaca gccctctccc aagacaatca gacgacaatg gatgaaactc: gatitatttt ccaactacgg caagacaatt ccgacagcag agcactgcta atccacaagt ccactacaaa tgagcaatgt aactttctgc attgctgcaa gttgaaacct cagcctcac cgcaggctct gtctaagact tgccatagat tgaggtgttt aagacctttg accacacctt gctatacatg <210> 2 <211> 93 <212> PRT <213> Homo sapiens <400> 2 Met Lys Leu Leu Met Val Leu Met Leu Ala Ala Leu Ser Gin His Cys Tyr Ala Gly Ser Gly Cys Pro Leu Leu Glu Asn Val Ile Ser Lys Thr 25 Ile Asn Pro Gin Val Ser Lys Thr GlU Tyr Lys Glu Leu Leu Gin Glu 40 Phe Ile Asp Asp Asn Ala Thr Thr Asn Ala Ile Asp Glu Leu Lys Glu 55 Cys Phe Leu Asn Gin Thr Asp Glu Thr Leu Ser Asn Val Glu Val Phe 70 75 Met Gin Leu Ile Tyr Asp Ser Ser Leu Cys Asp Leu Phe WO 00/1 8783 2 <210> 3 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence:Synthetic <400> 3 cagcggcttc cttgatcctt g <210> 4 <211> <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial sequence:Synthetic <400> 4 ataagaaaga gaaggtgtgg <210> <211> 403 <212> DNA <213> Homo sapiens PCT/US99/2261 6 <400) gacagcggct atgaagttgc ggctgcccct gaatacaaag gaattgaagg atgcaattaa gctcacagaa tccttgatcc tgatggtcct tattggagaa aacttcttca aatgttttct tatatgacag ctgcagggta ttgccacccg catgctggcg tgtgatttcc agagttcata taaccaaacg cagtctttgt tggtgagaaa cgactgaaca gccctctCc aagacaatca.
gacgacaatg gatgaaactc: gatttatttt ccaactacgg ccgacagcag agcactgcta atccacaagt ccactacaaa tgagcaatgt aactttctgc att cagcctcacc cgcaggctct gtctaagact tgccatagat tgaggtgttt aagacctttg <210> 6 <211> 206 <212> DNA <213> Homo sapiens <400> 6 tttatgcaat ttggctcaca cttctctttc atgtttattt taatatatga gaactgcagg ttatgtcttt taataaattg cagcagtctt tgtgatttat tttaactttc tgcaagacct gtatggtgag aaaccaacta cggattgctg caaaccacac ttactacaaa ctacaagaca attgttgaaa cctgctatac atggca <210> -1 <211> <212> PRT <213> Homo sapiens <400> 7 Met Lys Leu Val Phe Leu Phe Leu Leu Val Thr 1 5 10 Ile Pro Ile Cys Cys Tyr Ala Ser Gly Ser Gly Cys Ser Ile Leu Asp Glu, Val Ile Arg Gly 25 Thr Ile Asn Ser Thr Val Thr Leu His Asp Tyr Met Lys Leu Val Lys 40 Pro Tyr Val Gin Asp His Phe Thr Glu Lys Ala Val Lys Gin Phe Lys 55 WO 00/18783 WO 00/ 8783PCTIUS99/2261 6 3 Gin Cys Phe Leu Asp Gin Thr Asp Lys Thr Leu Gin Asn Val Gly Val 70 75 Met Met Giu Ala Ile Phe Asn Ser Giu Ser Cys Gin Gin Pro Ser 90 <210> 8 <211> 91 <212> PRT <213> Homo sapiens <400> 8 Met Lys Leu Ala Val 1 5 Ser Ser Ala Ser Ala Thr Leu Leu Met Asp Phe Ser Pro Asp Gin Len Val Asp Thr Leu Met Gin Lys Ile Ala Thr Len Giu le Thr Pro Asp Met 55 Pro Gin 70 Gin Ser Val Thr 10 Ser Phe Tyr Gin Ala Gly Arg Giu 75 Cys Asn Len Ala Len Cys Cys Gin Arg Val Ile Gin Ala Ala Met Gin Len Ala Gin Leu Lys Lys Ser Ile Ile Lys Len <210> 9 <211> <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence:Synthetic <400> 9 cacgaattca ctatcgattc tggaaccttc agagg <210> <211> 38 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence:Synthetic <400> ctggttcggc ccacctctga aggttccaga atcgatag <210> 11 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence:Synthetic <400> 11 aatccgtagt tggtttctca. cc <210> 12 WO 00/18783 WO 0018783PCT/US99/2261 6 4 <211> <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic <400> 12 ctttctgcaa gacctttggc <210> 13 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic <400> 13 <210> 14 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial <400> 14 Glu Val Phe Met Gin Leu Ile Tyr Sequence: Synthetic Asp Ser Ser Leu Cys Asp Leu Phe <210> <211> 279 <212> DNA <213> Homo sapiens <400> atgaagttgc ggctgcccct gaatacaaag gaattgaagg atgcaattaa tgatggtcct tattggagaa aacttcttca aatgttttct tatatgacag catgctggcg tgtgatttcc agagttcata taaccaaacg cagtctttgt gccctctccc agcactgcta cgcaggctct aagacaatca atccacaagt gtctaaqact gacgacaatg ccactacaaa tgccatagat gatgaaactc tgagcaatgt tgaggtgttt gatttattt <210> 16 <211> <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence:Synthetic <400> 16 agcactgcta cgcaggctct <210> 17 <211> 74 <212> PRT <213> Homo sapiens <400> 17 Ser Gly Cys Pro Leu Leu Glu Asn Val Ile Ser Lys Thr Ile Asn Pro 1 5 10 WO 00/18783 WO 0018783PCT[US99/22616 Gin Val Ser Lys Thr Giu Tyr Lys Glu Leu Leu Gin Giu Phe Ilie Asp 25 Asp Asn Ala Thr Thr Asn Ala Ile Asp Glu Leu Lys Gin Cys Phe Len 40 Asn Gin Thr Asp Glu Thr Leu Ser Asn Val Giu Val Phe Met Gin Leu 55 Ilie Tyr Asp Ser Ser Leu Cys Asp Len Phe <210> 18 <211> 26 <212> DNA <2i3> Artificiai Sequence <220> <223> Description of Artificial Sequence: Synthetic <400> 18 cgcggatcca qgattgtcct gcagat 26 <210> 19 <211> 26 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic <400> 19 ccggaattcc catccctcta cccaga 26 <210> <211> 24 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic <400> ccacccatgg caaattccat ggca 24 <210> 21 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic <400> 21 tctagacggc aggtcaggtc cacc 24
Claims (9)
1. A method for detecting the presence of breast cancer cells in a patient comprising detecting the presence of a mRNA encoding a mammaglobin polypeptide in a sample from the patient wherein the mRNA specifically hybridizes to SEQ ID or a complement of SEQ ID NO:15 and wherein an elevated concentration of said mRNA above the concentration for a healthy individual indicates the presence of breast cancer cells.
2. The method of claim 1 wherein the detecting step further comprises the steps of: providing a polynucleotide that specifically hybridizes to SEQ ID NO: incubating the polynucleotide with the sample under conditions in which the polynucleotide can specifically hybridize with mRNA from breast neoplasia cells, and detecting the existence of a polynucleotide-mRNA hybridization complex.
3. The method of claim 2 wherein the polynucleotide comprises the complement of SEQ ID NO:15 or a fragment thereof.
4. The method of claim 3 wherein the polynucleotide is a cDNA encoding a mammaglobin polypeptide consisting of the amino acid sequence of SEQ ID NO:2.
5. The method of any one of claims 1 to 4 wherein the sample comprises lymph node tissue.
6. The method of claim 1 wherein the detecting step further comprises the steps of: teps of(a) producing a cDNA encoding the mammaglobin polypeptide from the mRNA using the reverse transcription method, providing two oligonucleotides which specifically hybridize to the cDNA to define a region of the cDNA to be amplified by the polymerase chain reaction method, wherein one of said oligonucleotides hybridizes under high stringency conditions to SEQ ID NO:1 and the other oligonucleotide hybridizes under high stringency conditions to the complement of SEQ ID NO:1, c) amplifying the cDNA region by the polymerase chain reaction method using the two oligonucleotides as primers, and d) detecting the presence of the amplified cDNA region. 44
7. The method of claim 6 wherein the one of said two oligonucleotides comprises SEQ ID NO:4 and the other oligonucleotide comprises SEQ ID NO:16.
8. leukocytes. The method of claim 6 or 7 wherein the sample comprises peripheral
9. The method of claim 1 wherein the detecting step further comprises the steps of: amplifying a target region in the mRNA encoding mammaglobin by the asymmetric gap ligase chain reaction, and detecting the presence of the amplified target region. DATED this 11 day of August 2003 WASHINGTON UNIVERSITY, By its Patent Attorneys, E. F. WELLINGTON CO., Wellington) BA.4261
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU62758/99A AU767962B2 (en) | 1996-05-31 | 1999-09-29 | Mammaglobin, a secreted mammary-specific breast cancer protein |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU59616/96A AU698823B2 (en) | 1995-05-31 | 1996-05-31 | DNA sequence and encoded mammary-specific breast cancer protein |
US09/162,622 US6566072B1 (en) | 1995-05-31 | 1998-09-29 | Mammaglobin, a secreted mammary-specific breast cancer protein |
US09/162622 | 1998-09-29 | ||
AU62758/99A AU767962B2 (en) | 1996-05-31 | 1999-09-29 | Mammaglobin, a secreted mammary-specific breast cancer protein |
PCT/US1999/022616 WO2000018783A1 (en) | 1998-09-29 | 1999-09-29 | Mammaglobin, a secreted mammary-specific breast cancer protein |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU59616/96A Addition AU698823B2 (en) | 1995-05-31 | 1996-05-31 | DNA sequence and encoded mammary-specific breast cancer protein |
Publications (2)
Publication Number | Publication Date |
---|---|
AU6275899A AU6275899A (en) | 2000-04-17 |
AU767962B2 true AU767962B2 (en) | 2003-11-27 |
Family
ID=29782902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU62758/99A Expired AU767962B2 (en) | 1996-05-31 | 1999-09-29 | Mammaglobin, a secreted mammary-specific breast cancer protein |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU767962B2 (en) |
-
1999
- 1999-09-29 AU AU62758/99A patent/AU767962B2/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
AU6275899A (en) | 2000-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6677428B1 (en) | Mammaglobin, a secreted mammary-specific breast cancer protein | |
AU735338B2 (en) | Mammaglobin, a secreted mammary-specific breast cancer protein | |
AU2001276973B2 (en) | Compositions and methods for the therapy and diagnosis of ovarian cancer | |
US7202334B1 (en) | Compositions and methods for the therapy and diagnosis of ovarian cancer | |
US6962980B2 (en) | Compositions and methods for the therapy and diagnosis of ovarian cancer | |
AU2001276973A1 (en) | Compositions and methods for the therapy and diagnosis of ovarian cancer | |
WO1999038973A2 (en) | Compounds for therapy and diagnosis of lung cancer and methods for their use | |
US6566072B1 (en) | Mammaglobin, a secreted mammary-specific breast cancer protein | |
JP2002525098A5 (en) | ||
AU767962B2 (en) | Mammaglobin, a secreted mammary-specific breast cancer protein | |
NZ567750A (en) | Compositions and uses for cancer therapy | |
JP2003502028A (en) | Compositions and methods for treating, diagnosing and monitoring breast cancer | |
MXPA00002810A (en) | Mammaglobin, a secreted mammary-specific breast cancer protein | |
AU2007216683B2 (en) | Compositions and methods for therapy and diagnosis of ovarian cancer | |
JP4942906B2 (en) | Compositions and methods for treatment and diagnosis of ovarian cancer | |
CZ2000993A3 (en) | Mammaglobin, secreted protein specific for mastocarcinoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) |